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ABSTRACT
EXPLOITATION OF METABOLIC CHECKPOINTS IN CANCER CELLS
by
Deven Patel
Advisor: Dr. David A. Foster
During the G1 phase of the cell cycle, normal cells respond to growth factors and
nutrients prior to entering S-phase to replicate its genome. We previously reported that the growth
factor-mediated restriction point is distinguishable from a series of late G1 metabolic checkpoints
mediated by essential amino acids (EAAs), the conditionally essential amino acid glutamine (Gln),
and mTOR – the mammalian target of rapamycin. Mutations in genes encoding proteins that
regulate G1 cell cycle progression are observed in virtually all cancers. We observed that cancer
cells with K-Ras mutations bypass the late G1 Gln checkpoint when deprived of Gln and instead
arrest in S-phase. Significantly, this created a synthetic lethality for rapamycin. Whereas
rapamycin arrests cells in late G1, in S-phase rapamycin induces apoptosis. While depriving cells
of Gln can be achieved in culture, this is not a viable option in an animal. However, K-Ras-driven
cancer cells utilize Gln via a novel transaminase reaction whereby Gln is first deaminated to
glutamate and then glutamate is deamidated to a-ketoglutarate, with the concomitant conversion
of oxaloacetate to aspartate. This transamination reaction can be inhibited by aminooxyacetate,
which mimics Gln deprivation and causes S-phase arrest – creating synthetic lethality for
rapamycin.
Since S-phase arrest created a synthetic lethality for rapamycin, we investigated the
molecular basis for the S-phase arrest. We found that S-phase arrest was due to an inability to
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generate deoxynucleotides needed for DNA synthesis in the absence of glutamine. The lack of
Gln suppressed deoxynucleotides biosynthesis, which in turn induced replicative stress. The
replicative stress activated the ataxia telangiectasia and Rad3-related protein (ATR)-mediated
DNA damage pathway, which caused S-phase arrest. Of significance, aspartate, which is a critical
metabolite for deoxynucleotides biosynthesis and is generated by the transaminase reaction
between glutamate and oxaloacetate, rescued the S-phase arrest caused by inhibition of glutamine
utilization.
The presence of distinct metabolic checkpoints in late G1 for EAAs and Gln led us to
look for additional checkpoints that monitor the presence of critical nutrients. Since lipids are
critical for membrane biosynthesis, we investigated whether serum lipids were important for G1
cell cycle progression. We found that when put in delipidated serum, cells arrest in late G1 at a
distinct site downstream from the Gln checkpoint and upstream from the mTOR site. Intriguingly,
this checkpoint is dysregulated in clear cell renal carcinoma cells. These cells continue to replicate
in the absence of lipids until they ultimately starve themselves to death.
In summary, we have identified a series of late G1 metabolic checkpoints that are
dysregulated in specific cancer cell lines. It is speculated that when these checkpoints are
dysregulated in cancer cells, there are novel opportunities for therapeutic intervention.
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Chapter 1: Introduction
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Mammalian Cell Cycle
The cell cycle is a series of events that take place in order to duplicate the cell’s DNA
content and to divide one parent cell into two daughter cells. The mammalian cell cycle is divided
into several phases as follows: Gap-1 (G1) phase, Synthesis (S) phase, Gap-2 (G2) phase and
Mitotic (M) phase. During G1 phase, it gets the signals from growth factors and decides whether
it is appropriate to duplicate the genome. During S phase, cells replicates their genome. During G2
phase, cells check for any anomalies that could happen during the replication process and verify
the integrity of the replicated DNA. After G2 phase, cells enter M phase where cytokinesis occurs
and cells divide themselves into two daughter cells.
In normal proliferating cells, these events are so tightly regulated by a defense mechanism
called “Checkpoints” that if anything goes wrong, cells activate this checkpoint machinery and
halt the cell cycle progression until the damage is resolved. There are several checkpoints across
the cell cycle phases. The first checkpoint is Restriction point (R) in G1 phase, where the cells
commit to cell cycle entry and chromosome duplication. The second is DNA damage mediated
checkpoint in S and G2 phase where it verifies the integrity of the genome that is replicated during
S phase. The third is in the mitotic phase where it leads to chromosome alignment on the spindle
in metaphase. The checkpoints act as a control system to validate certain requirements which if
met, allows the progression into the next phase if not, there will be a pause in the cell cycle
progression and halt them. (Fig. 1.1) The ability of cancer cells to grow and proliferate
uncontrollably is a result of a dysregulation in this checkpoint machinery.
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Figure 1.1- Mammalian cell cycle and cell cycle checkpoints. Different phases of cell cycle and
progression through the checkpoints.

If cells are deprived of growth factors prior to R, they exit the cell cycle into a state of
quiescence known as G0. Anders Zetterberg and colleagues have carefully mapped that the time
it takes to reach R from mitosis is about 3 to 4 hours- a time course that was consistent for virtually
all cell lines examined [1-3]. Alongside with growth factors, cells also sense nutrients during G1
phase of the cell cycle. Studies by Hartwell and colleagues described a site in late G1 in yeast cells
where, upon absence of nutrients, cells arrest [4]. This site was called START and has been
referred to as the equivalent of the mammalian R. However, START is not sensitive to growth
factors as the yeast cells respond only to nutrients availability. This significant difference may
provide us a clue in order to better understand the confusion as to what R actually represents and
where R is located in G1. To get through START, cells rely on mammalian/mechanistic Target of
Rapamycin (mTOR) [5] which has been widely implicated in sensing nutritional needs in both
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yeast and mammalian cells [6, 7]. Blenis’ group and others have shown that treatment with
rapamycin, an inhibitor of mTOR, arrests cells in late G1 phase [8, 9] at a site that is consistent
with START. Notably, cells arrested with rapamycin were smaller than their counterparts, [8, 9]
consistent with a role for mTOR as a nutritional sensor that restricts cell growth in the absence of
adequate nutrients. Previous studies from our lab have validated this conundrum and shown R and
START as being distinguishable from one another. We have shown R to be a growth factorsensitive site where cells acquire signals from growth factors to avoid quiescence and START
senses whether there are enough nutrients for a cell to double its mass and divide [10]. Ability of
rapamycin to arrest cells in late G1 indicates that START may be conserved in mammalian cells
as a distinct checkpoint that senses nutritional sufficiency. This mTOR- dependent nutrient sensing
checkpoint could more appropriately be referred to as a “Cell Growth” checkpoint.
Nutrient Sensing Metabolic and Cell Growth Checkpoints
START was originally defined as a commitment step in late G1 where cells confirm the
nutrient status prior to committing to replicating the genome and cytokinesis [4, 11]. The lack of
essential amino acids resulted in G1 cell cycle arrest. It has been shown that re-entry of Swiss 3T3
cells into cell cycle upon restoring amino acids is significantly faster than when cells have entered
upon restoring growth factors [12]. Saqcena et al. has provided evidence that the GF-mediated R
and nutrient sensing metabolic checkpoint are different and distinguishable [10]. Unexpectedly,
there are a series of nutrient sensing metabolic checkpoints mediated by essential amino acids
(EAAs) and the “conditionally” essential amino acid, glutamine, in the latter part of G1 phase of
the cell cycle followed by then cell growth checkpoint mediated by mTOR [10]. It is well
established that mTORC1 senses EAA [13].
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Figure 1.2- Nutrient Sensing and growth checkpoint [14]. After Completing mitosis, the first
obstacle cells face is to passing R to avoid quiescence. Passage through this site is dependent on growth
factor signaling leads to Cyclin D expression. After passing R, cells activate signals that indicate
sufficient materials for the cell to double in mass. This checkpoint is mTOR, which suppresses TGFbsignaling, which stimulates the expression of p27, which suppresses Cyclin E-CDK2.

It is also well known and shown by many groups that mTORC1 activity is stimulated by glutamine
[15]. Other than EAAs and glutamine, mTORC1 is also responsive to glucose [16], ATP levels
[17], phosphatidic acid [18] and perhaps lipids. mTOR is not fully active until it senses ATP, lipids
as well as glucose and so this may explain why nutrient sensing checkpoints mediated by EAAs
and glutamine are upstream of mTOR-cell growth checkpoint. Thus mTOR might be final
arbitrator that senses all the nutrient input before entering in S-phase to replicate its genome. The
metabolic checkpoint downstream from R shown by Saqcena, et al. are similar to the series of
checkpoints shown in yeast together known as START [4, 19], where nutrients adequacy is
assessed in an mTOR-dependent manner in yeast [5, 20]. It is likely that R evolved much later than
START as a means for multicellular organisms to regulate proliferation through intercellular
communication.

5

Mammalian Target of Rapamycin Signaling
mTOR- the mammalian target of rapamycin is a critical energy and nutritional sensor that
integrates intracellular and extracellular signals. TOR was originally discovered in yeast [21, 22]
and was found in mammals several years later [23-26]. mTOR is a serine/threonine protein kinase
that is conserved throughout evolution [27] and plays a vital role in cell cycle progression, cell
survival, cell metabolism [28, 29]. mTOR is found to be dysregulated in most cancers and thus
makes it a good therapeutic target.
mTOR exists in two complexes: mTOR complex 1 (mTORC1) and mTOR complex 2
(mTORC2). mTORC1 is comprised of five components: mTOR, the catalytic subunit of the
complex; regulatory-associated protein of mTOR (Raptor); mammalian lethal with Sec13 protein
8 (mLST8); Proline-rich Akt substrate 40 kDa (PRAS40); and DEP-domain-containing mTORinteracting protein (Deptor) [30]. These different components play a distinct role in mTORC1
activity. It has been proposed that Raptor is necessary for assembly of the complex and thus for
mTORC1 activity [31, 32]. The role of mLST8 is somehow unclear but loss of this protein does
not hinder activity or function of mTORC1 in vivo [33]. PRAS40 and Deptor are known to have
an inhibitory effect on mTORC1 [30, 34, 35]. Upon activation of mTORC1, it phosphorylates
PRAS40 and Deptor, which further reduces the binding of these inhibitory proteins to mTORC1
and consequently further activates mTORC1 signaling. mTORC2 consist of six different proteins:
mTOR; rapamycin-insensitive companion of mTOR (Rictor); mammalian stress-activated protein
kinase interacting protein (mSIN1); protein observed with Rictor-1 (Protor-1); mLST8; and
Deptor. mSIN1 has been known to stabilize the assembly of mTOR and Rictor thus establishing
the structural basis of mTORC2 [36, 37]. Unlike mTORC1, the role of mLST8 is more influential
in mTORC2 function, as knocking out this protein affects the stability and activity of the complex
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[33]. Just like mTORC1, Deptor is also inhibitory to mTORC2 activity [30]. In addition to all these
proteins, both these complexes interact with phosphatidic acid (PA), a lipid metabolite, that is
shown to be required for the stability of both the complexes [18, 38-40].
As shown in Fig. 1.3, mTORC1 receives signals from growth factors through the activation
of canonical insulin and Ras signaling pathways. Activation of these pathways leads to
phosphorylation of TSC2 by Akt [41, 42], by inactivating TSC2, inducing activation of mTORC1.
Akt can also activate mTORC1 in a TSC2-independent manner by phosphorylation of PRAS40,
which causes dissociation of PRAS40 from mTORC1 [34, 35, 43]. The energy status of the cell
also dictates the activity of mTORC1 through AMP-activated protein kinase (AMPK). At low
energy, AMPK gets activated and phosphorylates TSC2, thus reducing mTORC1 activity [44].
Additionally, AMPK can reduce mTORC1 by directly phosphorylating Raptor, causing
dissociation of complex [45]. mTORC1 senses the presence of amino acids and is activated in a
PI3K-Akt-TSC2-independent manner [46]. Rag proteins, a family of four related GTPases, interact
with mTORC1 and are necessary for activation of mTORC1 in the presence of amino acids [47].
Activation of mTORC1 leads to activation of various downstream effectors in order to achieve
cell growth. mTORC1 stimulates protein synthesis by phosphorylating the eukaryotic initiation
factor 4E (eIF4E)- binding protein 1 (4E-BP1) and the p70 ribosomal S6 kinase 1 (S6K1). The
phosphorylation of 4E-BP1 thwarts its binding to eIF4E, allowing eIF4E to promote capdependent translation [48].
The activation of S6K1 leads to mRNA biogenesis, cap-dependent translation of ribosomal
proteins and elongation through regulation of proteins like ribosomal protein S6 [49]. mTORC1
also controls autophagy through phosphorylation of unv-51-like-kinase 1 (ULK1) and autophagyrelated gene 13 (ATG13) [50, 51]. mTORC1 also regulates lipid biogenesis by regulating sterol
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regulatory element binding protein 1 (SREBP1) [52]. Manning, et al has shown that S6K1
activation by mTORC1 leads to phosphorylation of CAD (Carbamoyl-phosphate synthetase 2,
Aspartate transcarbamoylase, dihydroorotase), an enzyme involved in de novo pyrimidine
synthesis [53].

Figure 1.3- Two complexes of mTORC1 and mTORC2 [54]. mTOR complexes are formed by
different partners and have distinct downstream effectors.

On the contrary to mTORC1, very little is known about mTORC2. It has been known that
mTORC2 kinase activity is increased upon activation of growth factor signaling [55]. mTORC2
is involved in cell survival, metabolism, proliferation and cytoskeletal organization. Deletion of
mTORC2 components causes a lethal phenotype, explains its importance in the previously
mentioned role. One of the important downstream effectors is Akt. Full activation of Akt via
phosphorylation at Ser308 by phosphoinositide-dependent kinase 1 (PDK1) and Ser473 by

8

mTORC2 leads to activation of its downstream effectors such as forkhead box protein O1
(FOXO1) and FoxO3a transcription factors, which controls many genes responsible for
metabolism, cell cycle arrest and apoptosis [56].
Another downstream effector of mTORC2 is serum and glucocorticoid-induced protein
kinase (SGK1), which shares homology with Akt [57]. mTORC2 controls the actin cytoskeleton
by promoting protein kinase C ɑ (PKCɑ) phosphorylation and GTP loading of RhoA and Rac1.
Rapamycin
Rapamycin, a macrolide antibiotic found in the Eastern Island of South Pacific is a
naturally produced by the bacterium Streptomyces hygroscopicus. In 1975, it was originally
defined as an antifungal agent as it caused G1 cell cycle arrest [58] and later it was found to have
immunosuppressant properties [22]. Rapamycin is an allosteric inhibitor of mTORC1. Rapamycin
binds with FK506-binding protein of 12 kDa (FKBP12) and interacts with the FKBP12-rapamycin
binding domain (FRB) of mTOR, causing inhibition of mTORC1 [55].
FKBP12-rapamycin cannot interact with mTORC2, thus having no effect on mTORC2
[59]. However, later it had been shown that chronic treatment of rapamycin inhibits mTORC2
activity by hindering its assembly formation in a tissue-type dependent manner [60]. Phosphatidic
acid (PA) activates mTOR by binding to its FRB domain and has been shown to compete with
rapamycin to bind to the FRB domain of mTOR [39].
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Rapamycin

Figure 1.4- Structure and Application of Rapamycin
Since rapamycin affects mTORC2 to a much lesser extent than mTORC1, a second
generation of mTOR inhibitors were developed to inhibit both mTORC1 and mTORC2, namely
Torin 1, PP242, Ku-0063794, WAY600, AZD8055 [61]. As expected these second-generation
inhibitors can inhibit cell growth and proliferation in vitro and tumor growth in vivo better than
rapamycin [62, 63]. They could suppress both mTORC1 and mTORC2. However, the use of
second generation of mTOR inhibitors could not be widely used due to higher toxicity- the
concentration of these drugs was not tolerable to patients and produced off-target effects. Since
rapamycin provides better specificity towards mTOR, it calls for elucidating the complete potential
of rapamycin. Thus, rapamycin’s potential as an anticancer drug requires further investigation.
Although the apoptotic and anti-proliferative effects of rapamycin have been demonstrated
by Vivanco, et al in head and neck squamous cell carcinoma, overall rapamycin has not been
proven effective against most cancers. As rapamycin has poor solubility, a vast number of
analogues of rapamycin have been developed and are referred to as rapalogs. In 2007, the rapalog
temsirolimus was approved by FDA for the treatment of advanced stage renal cell carcinoma,
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making it the first mTOR inhibitor approved for therapy. Recently another analog everolimus was
approved for the treatment of tuberous sclerosis, an autosomal dominant disorder in the brain [64].
It has long been known that low doses of rapamycin are not enough to target 4EBP-1 [65]. High
doses of rapamycin are required for complete inhibition of mTORC1 [66]. It is postulated that the
limited efficacy of rapamycin is due to its ability to perform as a cytostatic drug rather than
cytotoxic. It arrests cells in G1 phase of the cell cycle and growth arrest prevents them from
undergoing apoptosis. Rapamycin causes TGF-β-mediated cell cycle arrest which is discussed in
detail in the following section. Another shortcoming of using rapamycin based therapy is it
activates survival signals by activation of Akt by inhibiting phosphorylation of IRS-1 which will
be discussed in detail in the following sections.
TGF-β Signaling
Transforming Growth Factor-β (TGF-β) is a multifunctional autocrine/paracrine growth
regulator [67]. TGF-β is known to have a role in biological processes like embryonic development,
wound healing and angiogenesis in almost all type of cells.
The role of TGF-β is somewhat controversial. Under normal conditions, it restricts cell
growth, differentiation and cell death [68-70]. TGF-β is a tumor suppressor for early stages of
cancer and associated with poor patient prognosis and increased frequency of metastasis [71].
The binding of TGF-β to the TGF-β receptor II (TβRII) receptor kinase activates via
autophosphorylation followed by coupling with TGF-β receptor I (TβRI). TβRI then
phosphorylates Smad family proteins, which are downstream effectors of the TGF-β signaling
pathways. (Fig. 1.5) Smad-2 and Smad-3 are phosphorylated by TβRI at their C-terminal SSXS
residues. Phosphorylated Smad-2 and 3 then form a complex with Smad-4.
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TGF-b

Smad-2
TGF-b receptors
P
Smad-2
Smad-4
P
p27 Regulation

Smad-2
Smad-4

Nucleus
Figure 1.5- Transforming Growth Factor (TGF-b) signaling. TGF-b regulates the growth and
proliferation of cells. TGF-b binds with TβRI and dimerization of receptors causes phosphorylation of
SMAD2. SMAD2 then binds to SMAD4. This complex moves to nucleus and form complexes that
regulates transcription of cell cycle regulators.

In turn this complex translocates to the nucleus and start the transcription of cell cycle
regulator proteins such as p27, which has an inhibitory effect on cell cycle progression [72]. TGFβ is negatively regulated by Smad-6 and Smad-7. TGF-β signaling is often compromised in many
pancreatic and colon cancer cells due to mutation in its downstream effectors or insensitivity in
ligand binding.
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Figure 1.6- Rapamycin activates TGF-β signaling via inhibition of mTOR (Adapted from [73])

As shown in the Fig. 1.6, activation of mTOR has been known to relieve this TGF-β
signaling and allow cells to progress through late G1 phase of the cell cycle and enter S-phase.
Thus, when rapamycin is added and mTORC1 is inhibited; that will release this inhibition on TGFβ signaling caused by an active mTOR and will result in p27 accumulation in cells, leads to G1
cell cycle arrest [73].
Negative feedback loop activation upon rapamycin treatment
Biological systems maintain homeostasis due to physiological stresses by employing
certain mechanisms, such as negative feedback. Such a mechanism exists in growth factor
signaling where it is a universal mechanism for limiting the extent and duration of signaling output.
Recently, several studies have pursued to determine the implication of feedback regulation of
pathways that are driven by activated oncoproteins, which are usually constitutively expressed in
tumors. Tumor cells are known to be “addicted” to oncoproteins. Amit, et al has studied the effect
of EGF-dependent numerous negative feedback components including proteins that downregulate
ERK and ERK-mediated transcriptional programs [74]. Several other studies have also shown that
the components involved in the negative feedback loop in EGFR signaling in cancer cells were
found to be under expressed in tumors. Many drugs have been targeting oncoproteins that
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downregulate the pathways but also relieve such feedback inhibition of other pathways in the
network, resulting in resistance to the therapy or activation of survival mechanisms.
Growth Factors Signaling

LY294002

Growth Factors receptors

PI3K

mTORC2

IRS-1
Akt

Survival

Nutrients

Rapamycin
and
Rapalogs

mTORC1
S6K1

Figure 1.7- Rapamycin inhibits S6K1-mediated IRS1 degradation and activates PI3K/Akt pathway

Such consequence has been extensively studied in recent years and that is the case for drugs
targeting the PI3K/Akt/mTOR pathway. It had been previously established that IGF/Insulin
pathways are restricted by the feedback inhibition of the expression of insulin receptor and insulin
receptor substrates (IRS1,2).
As shown in the Fig. 1.7, mTOR phosphorylates S6K1, thus activating it, and in the
process, activated S6K1 phosphorylates the IRS and reduces their interaction with the IGF
receptors via degradation [75]. As shown by several groups, rapamycin relieved this S6K1dependent feedback loop and activates Akt which then provides survival signals to the cancer cells
[76, 77]. As the cells were treated with rapamycin, IRS proteins were stabilized and led to
reactivation of PI3K/Akt axis of the growth signaling pathways. The reactivation of the feedback
loop attenuated the efficacy of rapamycin in cancer cells.
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Metabolic Reprogramming in Cancer Cells
Unlike normal proliferating cells, cancer cells are surrounded by a different
microenvironment where they do not have adequate oxygen and nutrient conditions. As a result of
this, cancer cells adapt to the hypoxic and hypo-nutrient conditions in order to maintain growth
and proliferation. This phenomenon of adaptive response is often called “metabolic
reprogramming” and has been acknowledged as one of the hallmarks of cancer [78]. The Warburg
effect, also known as aerobic glycolysis, explained by Otto Warburg, is how cancer cells exhibit
an ability to process glucose into lactate even in the presence of adequate oxygen [79]. It has been
widely accepted as metabolic reprogramming, and recent advances have established that tumor
cells also depend on mitochondrial metabolism as well as aerobic glycolysis. Mutations in several
oncogenes and tumor suppressors have been shown to upregulate many metabolic enzymes,
resulting in metabolic reprogramming [80-82]. Cancer cells become growth autonomous and
evade growth factor dependence by gaining mutations in cell signaling pathways responsible for
growth. Recent advances have shown that over-activation of these signaling pathways alters the
metabolic signature of these cancer cells. Difference in metabolic profiles in cancer cells, in some
cases, is responsible for failure to induce therapeutic response. In some cases, metabolites
themselves can be oncogenic by altering cell signaling and blocking cellular differentiation [83].
Metabolism is one of the processes that is required to maintain energy homeostasis for a
complicated process of growth and a means to provide enough raw materials to generate daughter
cells. Thus, targeting metabolism is a good strategy to target cancer cells over normal proliferating
cells. A thorough understanding of altered and adapted metabolism will enable us to find a new
target for therapeutic interventions.
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Glutamine Metabolism
Glucose has been critical to the study of cancer metabolism following Otto Warburg’s
discovery of aerobic glycolysis [84]. The role of glutamine in the cancer metabolism field has
slowly been appreciated given the part it plays in cell growth and metabolism. Since consumption
and dependence of glutamine in cancer cells is much higher to maintain energy homeostasis and
raw materials required to generate two daughter cells, it is considered a “conditionally” essential
amino acid.
Glutamine has been known to provide carbon to TCA cycle intermediates as well as
nitrogen to synthesize nucleotides as well as amino acids [85]. In rapidly dividing cells, citrate,
synthesized from Acetyl-CoA and oxaloacetate, exits the mitochondria and is used for lipid
synthesis. This exit creates a need for anaplerotic replenishment of TCA cycle intermediates
downstream of citric acid. Glutamine has been known to feed into TCA cycle intermediates via
anaplerosis.
It does so in following manner: After being transported into mitochondria via transporters
[86], glutamine is first deaminated to glutamate via a glutaminase (GLS). This glutamate can be
used in several ways. One, glutamate is converted into ɑ-ketoglutarate via glutamate
dehydrogenase (GDH), producing ammonia [87]. The other pathway is via glutamate oxaloacetate
transferase (GOT), where glutamate is converted into ɑ-ketoglutarate (a-KG) with the
concomitant conversion of oxaloacetate into aspartate. Aspartate is also known to provide the
backbone for de novo nucleotide biosynthesis. Glutamate-pyruvate transaminase (GPT) also
transfers nitrogen from glutamate to pyruvate to make alanine and ɑ-ketoglutarate. Apart from
providing carbon to the TCA cycle intermediates, glutamine also provides nitrogen to synthesize
nucleotides and non-essential amino acids [85].
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Figure 1.8- Glutamine metabolism[88]. Gln is deaminated to glutamate by glutaminase (GLS). Then
Glutamate can be converted to a-ketoglutarate via either glutamate dehydrogenase (GDH) or
transamination reaction by glutamate oxaloacetate transaminase (GOT), where it generates aspartate, a
critical metabolite for nucleotides, amino acids, and NADPH production to maintain redox balance.
Aminooxyacetate inhibits GOT and inhibit the glutamine utilization in cells.

Glutamine donates its amide nitrogen directly to the purine and pyrimidine ring structures
to produce nucleotides, generating glutamate in the cytoplasm [89]. This glutamate then can enter
mitochondria via malate aspartate shuttle that is usually used to shuttle the electrons across the
mitochondria in exchange for aspartate. So, cells must generate enough aspartate in mitochondria
to exchange glutamate through this shuttle. Kimmelman and group has shown that K-Ras mutant
cells choose the GOT pathway over GDH pathway to generate a-KG and in the process, they
generate aspartate from oxaloacetate [90]. This study provides significance on how aspartate is
generated by K-Ras mutant cells to sustain this shuttle. Aspartate generated from glutamine
metabolism also plays an important role in providing its backbone to nucleotides. Recent studies
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have also shown aspartate derived from several metabolic pathways as being critical in dividing
cells for nucleotide biosynthesis, fatty acid metabolism [91], the urea cycle [92], and TCA cyclederived citrate [93, 94]. Such versatility makes glutamine metabolism an interesting therapeutic
option to target metabolically reprogrammed dividing cells.
DNA Damage Pathway
As briefly explained in the section about mammalian cell cycle, there are checkpoints in S
and G2 phase of the cell cycle where cells activate pathways to correct any error, that have occurred
during the process of replication. It provides an extra layer of defense against induction of
mutagenesis in eukaryotes. Precise duplication of the genome during S-phase is one of the most
important and vital processes in order to proliferate [95]. It is an irreversible process where once
the replication fork is formed, they are committed to the process. At this point they arrest in cell
cycle, and if the damage is not repairable, they undergo apoptosis. Under DNA damage, cells
invoke an activation of signaling pathways which causes an arrest or apoptosis. These pathways
get activated in response to either double stranded breaks (DSBs) or single stranded breaks (SSBs)
of the DNA. The single stranded DNA breaks trigger the ataxia telangiectasia mutated and Rad3related (ATR) Kinase pathways and double stranded DNA breaks trigger ataxia telangiectasia
(ATM) kinase pathways, the master regulators of two major checkpoint pathways [96]. The ATR
kinase is the principal activator of the replication stress response [96-98]. It is a member of serinethreonine kinases family, that includes ATM, mTOR, DNA-PK and SMG-1 [99]. ATR induces
the S-phase arrest via phosphorylation of the Chk1 kinase, which targets Cdc25A phosphatase for
degradation [100, 101], which is responsible for cell cycle progression through S-phase. The
activation of Chk1 by phosphorylation via ATR, further phosphorylates p53 at Ser15 site, and
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phosphorylates MDM2 protein, having inhibitory effect that normally negatively regulates p53
[102].
Lipid Metabolism
Lipids are large biomolecules that are utilized to synthesize plasma membranes in a newly
generated cell, signal transduction, and generation of extracellular vesicles. The structure of the
lipids mainly defines the flexibility of the membranes and can provide resistance to
chemotherapeutic drugs [103, 104]. Lipid metabolism plays a key role in cancer cell survival and
proliferation under stressful conditions. In adults, de novo synthesis of lipids is restricted mainly
to liver and adipose tissues, while the lipid demand, by other tissues are fulfilled by lipids
circulating in blood. Earlier it was shown that studies done with radio-labeled glucose, lipids were
found labeled which indicated that tumor cells can utilize their carbon from glucose to synthesize
their own lipids [105]. Since then, it has been shown that many cancers have overexpression of
fatty acid synthase (FASN), an enzyme responsible for fatty acid synthesis [106, 107]. Although
research in lipid metabolism has been mainly focused on lipid anabolism, lipid catabolism is also
important for cancer cell survival. One such example is monoacylglycerol lipase, which catalyzes
the release of fatty acids from intracellular lipid droplets, promoting growth and survival [108].
Another group has also shown that fatty acid oxidation induces resistance to radiation and
chemotherapeutic agents [109].
Hypoxia plays an important role in the metabolic reprogramming of cancer cells. Several
studies have shown that under hypoxic conditions, hypoxia inducing factor-1a (HIF-1a) plays an
important role in upregulation of glycolysis by induction of glucose transporters [83]. Likewise,
hypoxic cells choose glutamine over glucose to synthesize fatty acids through upregulating
reductive carboxylation [83, 110]. In clear-cell renal cell carcinomas (ccRCC), there is
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constitutively activation of HIFs due to loss of the von Hippel-Lindau (pVHL) tumor suppressor,
which is required for oxygen-dependent suppression of HIFs [111]. pVHL-null ccRCCs maintain
HIF-2a expression [112] and that maintains growth of ccRCCs [113]. In ccRCCs, there is a clear
cell phenotype which is due to presence of intracellular lipid droplets (LDs), which is comprised
of neutral lipid core containing triglycerides and cholesterol-esters, surrounded by a phospholipid
monolayer and associated LD surface proteins [114]. There are two well cataloged functions of
lipid droplets: energy homeostasis and release of lipid species for membrane synthesis during
proliferation [114]. Enhanced lipid storage has been shown to alter lipid metabolism. Qiu, et al has
shown that HIF-2a-dependent lipid droplets in ccRCCs plays an important role in maintaining the
integrity of endoplasmic reticulum (ER), thus suppressing ER stress [115]. Understanding these
lipid droplets in ccRCCs could potentially provide a viable option to target and expose ccRCCs to
cytotoxic ER stress.
Project Rationale:
Previously, Gadir, et al. has shown that the cytostatic effect of rapamycin is attributed to
the activation of TGF-b signaling pathway, resulting in p27 accumulation, followed by cell cycle
arrest [73]. But in the same study, rapamycin could induce apoptosis if cells were pretreated with
Aphidicolin. Aphidicolin arrests the cells at the G1/S boundary. If cells were treated with
rapamycin after this point, cells were dying due to apoptosis even in the presence of serum/TGFb. After this late G1/S progression, TGF-b was not able to rescue cells by inducing p27 levels. So,
we speculated that rapamycin has different effects in different phases of the cell cycle, working as
a cytotoxic drug in S-phase and cytostatic in G1 phase where it activates TGF-b signaling pathway.
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Previously, we have observed and shown that K-Ras mutant cells, upon glutamine
deprivation, bypass the G1 mediated late checkpoint and arrest abruptly in S-phase, unlike K-Ras
non-mutant cells [10, 116]. Apart from providing carbon to the TCA cycle intermediates,
glutamine also provides nitrogen to nucleotides biosynthesis. In S-phase, cells require ample
amounts of nucleotides to replicate its genome. So, we speculated that these K-Ras mutant cells
after bypassing G1 mediated checkpoint, enter S-phase and stall in S-phase without having enough
nucleotides, due to lack of glutamine and glutamine derived aspartate and activation of the DNA
damage pathway due to replicative stress.
In the final chapter, we investigated if there is any lipid mediated distinct checkpoint in
late G1 along with EAAs and Q mediated checkpoints [10]. Lipids are also an important nutrient
necessary for plasma membrane synthesis and an integral part of signaling pathways. Phosphatidic
acid has been known to stabilize the assembly of mTOR complexes [39]. So, we speculated that
the lipid-mediated checkpoint is the same as the mTOR mediated checkpoint. Thus, we started
investigating into a checkpoint mediated by lipids.
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Chapter 2: Apoptotic effects of high-dose rapamycin occur in S-phase of the cell cycle
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Abstract
Mutations in genes encoding regulators of mTOR, commonly provides survival signals in cancer
cells. Rapamycin and its analogs have been used but have limited success in clinical trials to target
survival signals provided by mTOR in a variety of human cancers. Suppression of mTOR
predominantly causes the accumulation of cells in G1 phase of the cell cycle, whereas its effect in
other cell cycle phases remains largely unexplored. We report here that when synchronized MDAMB-231 breast cancer cells are allowed to progress from G1 phase to S, rapamycin activates the
apoptotic machinery with a concomitant increase in cell death. In Calu-1 lung cancer cells,
rapamycin activated a feedback loop that increases the phosphorylation of Akt at Ser473 in Sphase that mitigated rapamycin-induced apoptosis. However, sensitivity to rapamycin in S-phase
could be reestablished if Akt phosphorylation was suppressed. We recently reported that glutamine
(Q) deprivation causes K-Ras mutant cancer cells to aberrantly arrest primarily in S-phase.
Consistent with observed sensitivity of S-phase cells to rapamycin, interfering with glutamine
metabolism sensitized both MDA-MB-231 and Calu-1 K-Ras mutant cancer cells to the apoptotic
effects of rapamycin. The effect was not observed upon rapamycin treatment, when K-Ras nonmutant cells were arrested in G1 phase due to glutamine deprivation. Importantly, rapamycin
induced substantially higher levels of cell death upon glutamine deprivation than that observed in
cancer cells that were allowed to progress through S-phase after being synchronized in G1. We
postulate that exploiting metabolic vulnerabilities in cancer cells such as S-phase arrest observed
with K-Ras driven cancer cells deprived of glutamine, could be of great therapeutic potential.
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Results
G1 cell cycle progression into S-phase for MDA-MB-231 and Calu-1 cells
We previously reported that in the absence of TGF-b, many human cancer cells are killed by
rapamycin [66, 73, 117, 118]. In the presence of TGF-b, rather than killing the cancer cells,
rapamycin treatment had a cytostatic effect and these cells arrested in late G1 [10, 73]. This led us
to propose that rapamycin preferentially killed cancer cells that passed through G1 and entered Sphase [119]. We reported recently that Ras-driven cancer cells are more sensitive to treatments
that target cells that have entered S-phase [120]. We chose to investigate two K-Ras-driven cancer
cells – MDA-MB-231 breast and Calu-1 lung cancer cells, which we have used previously to
address the vulnerability of Ras-driven cancer cells that had entered S-phase [120, 121]. We
wanted to establish a G1 or G0 cell cycle arrest that was upstream from the late G1 site where
rapamycin arrests cells [10]. Using serum withdrawal to arrest cancer cells in G0 is problematic
because most cancer cells have acquired a mutation – such as Ras, which permits passage through
the growth factor-dependent restriction point [122]. We therefore arrested the cancer cells with
lovastatin, which causes G1 cell cycle arrest in both normal and cancer cells [123, 124]. The
lovastatin-induced G1 arrest can be overcome with mevalonic acid and the arrest occurs relatively
early in G1. MDA-MB-231 and Calu-1 cells were treated with lovastatin for 36 and 48 hours
respectively. The G1 arrested cells were then released from cell cycle arrest by placing in fresh
medium containing mevalonic acid. Mevalonic acid is the product of b-hydroxy-b-methylglutarylCoA (HMG-CoA) reductase- the target of lovastatin and the rate-limiting step in cholesterol
biosynthesis [125]. As shown in Fig. 2.1, treatment of asynchronous MDA-MB-231 and Calu-1
cells with lovastatin resulted in a shift to a predominantly G1 population of cells. Upon changing
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to fresh medium containing mevalonic acid to release from the lovastatin-induced G1 arrest, there
was a shift to a predominantly S-phase population of cells between 22 and 24 hrs. (Fig. 2.1A)
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Figure 2.1- Cell cycle progression from G1 into S-phase for MDA-MB-231 and Calu-1 cells.
(A) MDA-MB-231 breast cancer cells and Calu-1 lung cancer cells were plated at 30% confluence in
medium containing 10% Fetal Bovine Serum. After 24 hours, cells were synchronized using lovastatin as
described in Materials and Methods. Upon release from G1 block, cells were collected at indicated time
points and analyzed for cell cycle distribution by measuring DNA content using flow cytometry. Error bars
represent the standard deviation for experiments repeated at least 3 times. (B) Western blot analysis
performed to determine the levels of cyclin A, and actin. These data shown are representative of
experiments repeated at least 3 times.

We also examined the levels of Cyclin A, which is elevated as cells enter S-phase [126] during the
transition from lovastatin arrest in G1 to S-phase. As shown in Fig. 2.1B, there was an increase in
cyclin A levels that correlated with an increased population of S-phase cells. Thus, lovastatin

Figure'1,'Saqcena'et'al.'

25

induces G1 arrest in both MDA-MB-231 and Calu-1 cells, and upon restoring fresh medium
containing mevalonic acid, the cells proceed to S-phase. Given that the time course was longer
than the time required for progressing from mitosis to S, there is clearly a recovery period needed
to reprogram progression into S-phase.
mTOR inhibition by rapamycin enhances apoptosis in S phase of the cell cycle in MDAMB-231 cells but not in Calu-1 cells
Having established a time course for progression from lovastatin-induced G1 arrest to S-phase, we
investigated the ability of rapamycin to induce apoptosis in G1 relative to S-phase. We previously
reported that high (20µM) doses of rapamycin that suppress phosphorylation of 4E-BP1 were
required for rapamycin-induced apoptosis [66, 118]. MDA-MB-231 (Fig. 2.2A) and Calu-1 (Fig.
2.2B) cells were arrested in G1 with lovastatin as in Fig. 2.1 and then released with fresh medium
containing mevalonic acid. Upon release from lovastatin block, rapamycin was added at indicated
times for additional 24 hours after which apoptosis was assessed by measuring increase in cleaved
PARP levels. At 22 hours after release when the cells were entering S-phase, there was an increase
in PARP cleavage with rapamycin in MDA-MB-231 cells (Fig. 2.2A) but not in Calu-1 cells (Fig.
2.2B). Cell viability correlated with the levels of PARP cleavage induced by rapamycin for both
the MDA-MB-231 and Calu-1 cells (Fig. 2.2C). The Calu-1 cells survived even though
phosphorylation of 4E-BP1 was inhibited by rapamycin (Fig. 2.2B). Thus, rapamycin, at doses
that suppress 4E-BP1 phosphorylation, induced PARP cleavage in MDA-MB-231 cells when they
entered S-phase, whereas Calu-1 cells were resistant to the apoptotic effects of rapamycin.

26

A

MDA-MB-231
G1-phase

Release (hrs)
Rapamycin

8
-

20

16

12
-

+

+

-

S-phase

+

-

24

22
-

+

-

+

-

+

26
+

28
-

+

Cl-PARP
P-4EBP1T37/46
4EBP1
Actin

B

Calu-1

G1-phase
Release (hrs)
Rapamycin

20

16

12
-

+

-

+

-

S-phase
24

22
+

-

+

-

26
+

-

+

Cl-PARP
P-4EBP1T37/46
4EBP1
Actin

C
MDA-MB-231

Calu-1
45

45

Control

30

15

15

0

24

12

1

12

1

0

Rapamycin

30

1

% Non-viable cells

Rapamycin

1

% Non-viable cells

Control

24

Figure 2.2- mTOR inhibition by rapamycin enhances apoptosis in S-phase of the cell cycle in
MDA-MB-231 cells but not in Calu-1 cells.

MDA-MB-231 (A) and Calu-1 (B) cells were

synchronized in G1 phase of the cell cycle using lovastatin as in Fig. 2.1. Upon release from G1 block,
rapamycin (20µM) was added at indicated time points. After 24 hours, cells were collected and Western

Figure'2,'Saqcena'et'al.'

blot analysis was performed for cleaved PARP (Cl-PARP), P-4E-BP1(T37/46), 4E-BP1, and actin. These
data shown are representative of experiments repeated at least 3 times. (C) MDA-MB-231 and Calu-1 cells
were synchronized using lovastatin as in (A) and (B). Upon release from G1 block, the cells were treated
with rapamycin at 12 and 24 hours. Cells were collected 24 hours later and cell viability assays were
performed using trypan blue exclusion as described in Materials and Methods. Error bars represent the
standard deviation for experiment at least repeated 3 times.
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G1 block, the cells were treated with rapamycin and LY294002
at indicated times for 24 hours. Cells were
then collected and cell viability assays were performed as in Fig. 2.2 C. Error bars represent the standard
deviation for experiment at least repeated 2 times.

So, in the previous data reveal that while rapamycin induced apoptosis in MDA-MB-231 cells in
S-phase, Calu-1 cells were resistant to this treatment. We reported previously that elevated
phosphorylation of Akt at Ser473 can inhibit rapamycin-induced apoptosis in pancreatic cancer
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cells [117]. Previous reports have shown that inhibition of mTORC1 with rapamycin elevates Akt
phosphorylation in some cancer cells including Calu-1[76, 127]. Since the Akt is well known to
provide survival in cancer cells [128, 129], we investigated whether suppressing Akt
phosphorylation at Ser473 would make Calu-1 cells susceptible to rapamycin. To determine that
possibility, we investigated the effect of rapamycin in combination with the phosphatidylionositol3-kinase (PI3K) inhibitor LY294002, which suppresses Akt phosphorylation [117]. Calu-1 cells
were arrested in G1 phase with lovastatin and released with fresh medium and mevalonic acid as
in Fig. 2.1. As shown in Fig. 2.3A and 2.3B, rapamycin treatment led to elevated levels of Akt
phosphorylation at Ser473 at both 12 and 24 hours post release from lovastatin block. There was
a more drastic increase seen 24 hours post release and rapamycin treatment, which is consistent
with two recent reports indicating that phosphorylation of Akt at Ser473 is more prominent in Sphase [130, 131]. LY294002 suppressed the rapamycin-induced increase in Akt phosphorylation
in both G1 and S-phase (Fig. 2.3A and 2.3B). Along with the suppression of Akt phosphorylation,
there was a corresponding increase in PARP cleavage (Fig. 2.3B) and cell death (Fig. 2.3C) in the
S-phase Calu-1 cells. The elevated PARP cleavage and cell death seen with LY294002 alone (Fig.
2.3B and 2.3C) is likely because PI3K and mTOR are related kinases and LY294002 partially
inhibits mTOR as well as PI3K [132]. These data explain that the feedback activation of Akt via
suppression of mTORC1 [76, 127] suppresses the apoptotic machinery activated by rapamycin in
Calu-1 cells. However, suppression of Akt phosphorylation restores the sensitivity of S-phase cells
to rapamycin.
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Arresting K-Ras mutant cancer cells in S-phase by suppressing glutamine utilization enhances
rapamycin-induced apoptosis

Treating MDA-MB-231 cells with rapamycin and Calu-1 cells with rapamycin plus LY294002
when cells were progressing through S-phase resulted in elevated levels of cleaved PARP and an
increase in cell death (Figs. 2.2 and 2.3). However, the levels of PARP cleavage and cell death
was not as robust as was observed if cells were deprived of serum or if they were arrested in Sphase with Aphidicolin- an inhibitor of DNA synthesis [73]. We recently reported that K-Ras
driven cancer cells bypass a late G1 glutamine-dependent checkpoint [10] and instead arrested in
S-phase [116]. We therefore examined whether rapamycin, which apparently induces apoptosis in
S-phase cells specifically, induces apoptosis in K-Ras mutant cancer cells when glutamine is
deprived or its utilization is inhibited pharmacologically. We used two means to suppress
glutamine in the cells: 1) using medium lacking glutamine; and 2) blocking anaplerosis utilization
of glutamine with Aminooxyacetate (AOA), which interferes with the transamination reaction
whereby glutamate is deaminated to a-ketoglutarate while oxaloacetate is aminated to aspartic
acid by the enzyme called glutamate-oxaloacetate-transaminase (GOT) [133]. MDA-MB-231 and
Calu-1, K-Ras mutant cells arrested largely in S-phase and we used MCF-7 breast cancer cells as
a negative control- K-Ras non-mutant cells which arrest in G1 in response to glutamine
deprivation. (Fig. 2.4A) AOA treatment mimics the growth arrest observed in K-Ras mutant cells
as well as K-Ras non-mutant cells S and G1-phase respectively (Fig. 2.4A). We next examined the
effect of rapamycin on MCF-7 and MDA- MB-231 cells that had been subjected to glutamine
deprivation or AOA treatment. As shown in Fig. 2.4B, treatment of MCF-7 cells, which largely
arrest in G1 phase, did not result in significant cell death although there was some PARP cleavage
upon rapamycin treatment by itself- a phenomenon we have observed previously [134].
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Figure 2.4- Glutamine starvation causes S phase arrest in K-Ras mutant cell lines and
sensitizes them to rapamycin. (A) MCF7, MDA-MB-231, and Calu-1 cells were plated at 30%
confluence. After 24 hours, cells were shifted to medium lacking glutamine or complete medium containing
AOA (0.5 mM) for 48 hours. Cells were collected and analyzed for cell cycle distribution by measuring
DNA content using FACS analysis. Error bars represent the standard deviation for experiments repeated at
least repeated 3 times. (B) MCF-7 and MDA-MB-231 cells were arrested in S phase as described in (A).
After 48 hours, cells were additionally treated with Rapamycin for 24 hours. Cells were collected and
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Western blot analysis was performed for cleaved PARP, P-Akt (S473) phosphorylation and actin. Cell
viability was determined as in Fig. 2.2C. Error bars represent the standard deviation for experiments
repeated 3 times. (C) Calu-1 cells were arrested in S phase as in (A). After 48 hours, cells were treated
with Rapamycin and LY294002 for 24 hours where indicated. Cells were then collected and Western blot
analysis and cell viability assays were performed as in (B). Error bars represent the standard deviation for
experiments repeated 3 times.

This presumably reflects a subpopulation of S-phase cells in both glutamine deprivation and AOA,
which arrest cells in G1, prevented the rapamycin-induced PARP cleavage. However, in the MDAMB-231 cells, rapamycin induced PARP cleavage in cells that had either been deprived of
glutamine, or where glutamine utilization via GOT was blocked by AOA (Fig. 2.4B). For Calu-1
cells, we employed LY294002 along with rapamycin. What was observed was somewhat
unexpected in that both glutamine deprivation and AOA elevated Akt phosphorylation at Ser473
and surprisingly rapamycin no longer stimulated Akt phosphorylation and, in fact, suppressed the
phosphorylation stimulated by glutamine deprivation and AOA (Fig. 2.4C). Importantly
rapamycin stimulated PARP cleavage and loss of cell viability in the absence of LY294002 (Fig.
2.4C). The PARP cleavage and the loss of cell viability were substantially stronger in the cells that
were arrested in S-phase (Fig. 2.4) than those that were passing through S-phase (Fig. 2.2 and 2.3).
The data in Fig. 2.4 demonstrate that K-Ras mutant cancer cells that are arrested in S-phase and
perhaps G2/M phase by interfering with glutamine utilization are highly sensitive to the apoptotic
effects of rapamycin.
Discussion
In this study, we have provided evidence that the apoptotic effects of rapamycin occur after
transition from G1 into S-phase of the cell cycle. Prior to enter into S-phase, rapamycin causes
TGF-b-dependent cell cycle arrest at a site late in G1 [10]. While the apoptotic machinery was
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clearly activated by rapamycin when cells synchronized in G1 were allowed to progress
synchronously to S-phase, cell viability was reduced much more substantially if the cells were
arrested in S-phase. Of significance, S-phase arrest could be accomplished in cancer cells
harboring K-Ras mutations by interfering with glutamine utilization. Thus a synthetic lethality for
rapamycin can be created by exploiting the ability of K-Ras mutant cancer cells to override a late
G1 glutamine checkpoint and arrest in S-phase [116]. Thus, the cell cycle specificity for the
apoptotic effects of rapamycin offers novel therapeutic options for the large number of K-Ras
mutant cancers.
There was a complication with the rapamycin strategy resulting from a feedback activation
of mTORC2 and the phosphorylation of Akt at Ser473. In response to suppressing the
phosphorylation of S6K by mTORC1, there is an IGF1 receptor-dependent increase in
phosphorylation of Akt at Ser473 [76, 127]. This was observed in Calu-1 cells used in this study
where the feedback stimulation of Akt phosphorylation suppressed the activation of the S-phase
apoptotic effects of rapamycin. Rapamycin did not stimulate the feedback activation of Akt in the
MDA-MB-231 cells. We have seen a similar resistance to rapamycin-induced apoptosis created
by induction of Akt phosphorylation in pancreatic cancer cells with defective TGF-b signaling
[117]. In the previous study with pancreatic cancer cells, like Calu-1 cells, suppressing Akt
phosphorylation restored the apoptotic effect of rapamycin. Thus, activated Akt can overcome the
apoptotic effect of rapamycin on S-phase cells- consistent with its known role as a survival kinase
[128]. It will therefore be important to know whether the feedback is active in a given cancer for
a rapamycin-based therapeutic strategy. However, a combination of suppressing both mTORC1
and mTORC2 could work. We used a catalytic mTOR inhibitor to achieve suppression of both
mTORC1 and mTORC2 and induce apoptosis and pancreatic cells and cells that has feedback
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activation loop for Akt [117]. It was also of interest and importance that in Calu-1 cells deprived
of glutamine, rapamycin inhibited, rather than stimulated Akt phosphorylation and was able to
induce the apoptotic effect in these cells that were arrested in S-phase. Thus, the feedback
stimulation of Akt phosphorylation may not be an issue if a strategy that employs glutamine
deprivation is used.

Figure 2.5- Model for cell cycle-dependent sensitivity to rapamycin. (A) Rapamycin
resistance. In most cells, the apoptotic effect of rapamycin is negated by a TGF-β-dependent late G1 cell
cycle arrest. Additionally, a feedback dependent increase in Akt phosphorylation in Akt phosphorylation at
Ser473 mitigates S-phase cytotoxicity of rapamycin. (B) Synthetic lethality. A synthetic lethality for
rapamycin could be achieved via one of the 3 mechanisms: (a) in cells with defective TGF-β signaling,
rapamycin treatment fails to arrest the cells in G1 phase and instead the cells progress into S-phase where
rapamycin causes apoptosis. (b) Feedback activation of Akt (S473) phosphorylation in S-phase is
suppressed with LY294002, and in absence of Akt-dependent survival signals, rapamycin induces apoptotic
cell death. And lastly, (c) in K-Ras mutant cancer cells, blockade of glutamine utilization causes the cells

34

to aberrantly arrest in S-phase [10]. Importantly, in this case, S-phase arrest is not accompanied with an
increase in Akt (Ser473) phosphorylation upon rapamycin treatment, and consequently, rapamycin induces
apoptotic cell death in the absence of Akt inhibition.

It is clear that micro-molar doses of rapamycin that suppress phosphorylation of 4E-BP1
are required [66]. Consistent with this hypothesis, suppression of 4E-BP1 expression prevented
the apoptotic effects of rapamycin [66]. Since the suppression of 4E-BP1 phosphorylation leads to
the sequestration of eIF4E and repressed cap-dependent translation [48], the observations reported
here implicate eIF4E as being critical for progression through S-phase. In this regard, it is of note
that eIF4E can induce tumorigenesis when dysregulated and overexpressed [135]. eIF4E promotes
the translation of proteins critical for cell cycle progression and survival [136]. Thus, when
mTORC1 is suppressed in S-phase, the cells are getting a signal that nutrient is sparse and since
the cell cycle is not reversible, default apoptotic signals are activated. It appears that if cells are
progressing through the S-phase, the majority of cells are able to survive rapamycin treatment and
the activation of the apoptotic machinery. However, if the cells are arrested in S-phase, then there
is substantial cell death caused by rapamycin. The arrest of K-Ras mutant cancer cells in S-phase
caused by interfering with glutamine utilization creates synthetic lethal phenotype for rapamycin.
Thus, a therapeutic approach that blocks the anaplerotic utilization of glutamine along with
rapamycin represents a plausible approach for treating the large number of human cancers driven
by K-Ras mutation.
According to our observations, cells were significantly vulnerable to rapamycin when they
were arrested in S-phase by Aphidicolin or glutamine deprivation. Aphidicolin is a DNA
polymerase-ɑ inhibitor, which affects the DNA replication machinery. It is not clear why
glutamine deprivation would make cells so sensitive to cytotoxic effects of rapamycin. The next
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chapter will focus on the investigating the molecular mechanism of the S-phase arrest caused by
glutamine deprivation in K-Ras mutant cancers.
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Chapter 3: Aspartate recuses S-phase arrest mediated by DNA damage pathway caused
due to suppression of glutamine utilization in K-Ras mutant cancer cells
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Abstract
During G1-phase of the cell cycle, normal cells respond first to growth factors that indicate that it
is appropriate to divide and then later in G1, to the presence of nutrients that indicate sufficient
raw material to generate two daughter cells. Dividing cells rely on the “conditionally essential”
amino acid glutamine (Q) as an anaplerotic carbon source for TCA cycle intermediates and as a
nitrogen source for nucleotides biosynthesis. We previously reported that while non-transformed
cells arrest in the latter portion of G1 upon glutamine deprivation, K-Ras mutant cancer cells
bypass the G1 checkpoint, and instead, arrest in S-phase. In this study, we report that the arrest of
K-Ras mutant cancer cells in S-phase upon glutamine deprivation is due to the lack of deoxy
nucleotides needed for DNA synthesis. The lack of deoxy nucleotides causes replicative stress
leading to activation of the ataxia telangiectasia and Rad3-related protein (ATR)-mediated DNA
damage pathway, which arrests K-Ras mutant cells in S-phase. The key metabolite generated from
glutamine utilization was aspartate, which is generated from a transaminase reaction whereby
glutamine-derived glutamate is converted to ɑ-ketoglutarate with the concomitant conversion of
oxaloacetate and aspartate. Aspartate is a critical metabolite for both purine and pyrimidine
nucleotides biosynthesis. This study identifies the molecular basis for the S-phase arrest caused by
glutamine deprivation in K-Ras mutant cancer cells that arrest in S-phase in response to glutamine
deprivation. Given that arresting cells in S-phase sensitizes cells to apoptotic insult, this study
suggests novel therapeutic approaches to K-Ras mutant cancers.
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Results
Deoxy nucleosides reverse the S-phase arrest caused by glutamine deprivation in K-Ras
mutant cancer cells
Since glutamine (Q) provides nitrogen for purine and pyrimidine nucleotides biosynthesis [137,
138], glutamine deprivation could disrupt the pool of available nucleotides in cells by interfering
with de novo purine and pyrimidine biosynthesis. To test this hypothesis, we subjected K-Ras
mutant MDA-MB-231 breast cancer cells, K-Ras non-mutant MCF-7 breast cancer cells, and noncancerous BJ-hTERT fibroblasts to Q deprivation for 48 hours. As observed previously, the MDAMB-231 cells arrested in S-phase, whereas the MCF-7 and BJ-hTERT cells arrested in G1 phase
upon Q deprivation [10, 116, 139]. (Fig. 3.1A) After 48 hours of Q deprivation, a mixture of deoxy
nucleosides was added exogenously and cell cycle progression was monitored by flow cytometric
analysis. As shown in Fig. 3.1A, we were able to reverse the S-phase cell cycle arrest caused by Q
deprivation with the addition of nucleosides to the MDA-MB-231 cells. The deoxy nucleosides
had no effect on the G1 arrested MCF-7 and BJ-hTERT cells (Fig.3.1A). These data indicate that
the S-phase arrest of the K-Ras mutant MDA-MB-231 cells induced by Q deprivation was due to
the depletion of deoxy nucleotides needed for DNA synthesis.
We next examined whether the deoxy nucleosides promoted cell proliferation in the MDAMB-231 cells deprived of Q. As shown in Fig. 3.1B, the addition of deoxy nucleotides promoted
cell proliferation in MDA-MB-231, but not in MCF-7 and BJ-hTERT cells, which were arrested
in G1 upon glutamine starvation. This finding demonstrates that providing deoxy nucleotides not
only allows progression through S-phase, but allows cells to undergo mitosis as well. The lack of
effect on MCF-7 and BJ-hTERT cells suggests that the Q requirement for nucleotides biosynthesis
is restricted to S-phase arrest only.
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Figure 3.1- Reversal of S phase arrest in K-Ras mutant cells upon exogenous addition of
nucleosides. (A) MDA-MB-231, MCF-7 and BJ-hTERT cells were plated at 30% confluence in 10 cm
plates in DMEM containing 10% fetal bovine serum (FBS). After 24 hours, cells were shifted to DMEM
containing or lacking Q for 48 hours. Both +Q and –Q medium contained 10% dialyzed fetal bovine serum.
At this point, cells were transferred into media lacking Q with or without nucleosides. The lysates were
collected at different time intervals and analyzed for cell cycle distribution by measuring DNA content/cell
using flow cytometric analysis. The error bars represent S.D. for experiments repeated for two times. p
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values for the S-phase population in MDA-MB-231, MCF-7 and BJ-hTERT cells, across the samples are
expressed relative to control Q. (B) Cells were plated and treated as in (A). Cells were harvested at indicated
time points, stained using crystal violet and quantified by light microscopy. Error bars represent S.D. for
experiments repeated for two times. (C) Cells were plated in 12-well plates with 30% confluence and shifted
to the media as explained in (A). After 48 hours of Q deprivation, cells were shifted to medium lacking Q
with or without deoxy nucleosides (dNSs) for 24 hours. [3H]-thymine deoxyribose (TdR) (20 Ci/mMol, 1
mCi/ml) was added for the last 2 hours of treatment. The samples were then subjected to scintillation
counting to measure labeled DNA. Values were normalized to the cpm for +Q, which were given values of
100%. Error bars represent S.D. for experiments repeated two times. (ns=p>0.05, *=p<0.05, **=p<0.01
***=p<0.001, ****=p<0.0001)

To further establish that the deoxy nucleotides were restoring DNA synthesis, we examined
the impact of deoxy nucleotides on DNA synthesis as indicated by the incorporation of [3H]thymine-deoxyribose (TdR). K-Ras mutant MDA-MB-231 breast and Calu-1 lung cancer cells
along with the K-Ras non-mutant MCF breast cancer cells and BJ-hTERT cells were subjected to
Q deprivation for 48 hours and then treated with the deoxy nucleosides mix for 24 hours as
indicated. [3H]-thymine-deoxyribose (TdR) was added for the last 2 hours at which time the cells
were harvested and the level of [3H]-(TdR) incorporation was determined. As shown in Fig. 3.1C,
Q deprivation resulted in the suppression of 80% of the [3H]-(TdR) incorporation in all the cell
lines. When deoxy nucleosides were provided, [3H]-TdR incorporation was restored in the S-phase
arrested MDA-MB-231 and Calu-1 cells, but not in the G1 arrested MCF-7 and BJ-hTERT cells.
These data demonstrate that DNA synthesis was restored by the presence of deoxy nucleosides in
Q-deprived K-Ras driven cancer cells.
Aspartate reverses the S-phase arrest in K-Ras mutant cancer cells

We previously reported that we could mimic Q-deprivation with the transaminase inhibitor AOA
[116], which blocks the conversion of Q-derived glutamate to ɑ-KG in K-Ras mutant cancer cells.
Importantly conversion of glutamate to ɑ-KG is coupled with the conversion of oxaloacetate to
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Figure 3.2- S-G2 phase arrest caused by inhibition of utilization of glutamine can be reversed
by addition of nucleosides and aspartate exogenously. (A) MDA-MB-231 and Calu-1 were plated
at 30% confluence in 10-cm plates in complete media (CM) containing 10% FBS. After 24 hours, cells
were shifted to medium containing or lacking 0.5 mM AOA for 48 hours. At this point, cells were
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transferred into media containing AOA with or without dNSs. Lysates were collected after 48 hours and
analyzed for cell cycle distribution by measuring DNA content/cell using flow cytometric analysis. Error
bars represent S.D. for experiments repeated two times. p values for the S-phase and G2-phase population
in MDA-MB-231 and Calu-1 cells respectively, across the samples are expressed relative to control Q. (B)
MDA-MB-231, Calu-1 and MCF-7 cells were plated and treated with AOA for 48 hours as in (A). Along
with AOA, cells were treated with cell permeable analogues of a-KG (DMKG; 4 mM) and aspartate (bMD, 10 mM). [3H]-thymidine deoxyribose (TdR) (20 Ci/mMol, 1 mCi/ml) was added for the last 24 hours
of the treatment. Cells were then subjected to scintillation counting to measure labeled DNA. Error bars
represent S.D. for experiments repeated two times. (C) MDA-MB-231, Calu-1 and MCF-7 cells were plated
and treated with AOA for 48 hours as described in (A). Along with AOA, cells were treated with the cell
permeable analogues of a-KG and aspartate. Cells were harvested after 48 hours and analyzed for cell cycle
distribution by measuring DNA content/cell using flow cytometric analysis. Error bars represent S.D. for
experiments repeated two times. p values for the S-phase in MDA-MB-231; MCF-7 and G2-phase
population in Calu-1 cells, across the samples are expressed relative to control Q. (ns=p>0.05, *=p<0.05,
**=p<0.01 ***=p<0.001, ****=p<0.0001)

aspartate by the enzyme GOT [90]. Thus, the inhibition of GOT with AOA suppresses not only
the production of ɑ-KG but also Aspartate. K-Ras mutant MDA-MB-231 and Calu-1 cells were
treated with AOA for 48 hours and as reported previously, the cells arrested in S and G2-phases
of the cell cycle [116, 139] (Fig. 3.2B). As was observed with Q deprivation in Fig. 3.1A, the Sphase arrest caused by AOA could be reversed with deoxy nucleosides (Fig. 3.2A). Thus, the Sphase arrest in K-Ras mutant cancer cells induced by inhibiting Q utilization with AOA can be
reversed by providing deoxy nucleosides. Of significance, aspartate is a critical metabolite in the
synthesis of purine and pyrimidines. We therefore examined whether the AOA-induced S-phase
arrest could be reversed by providing cell permeable analogues of ɑ-KG and/or aspartate- the
products of GOT. As shown in Fig. 3.2B, aspartate especially reversed AOA-induced suppression
of [3H]-TdR in MDA-MB-231 and Calu-1 cells, whereas ɑ-KG had very little effect. In contrast,
both aspartate and ɑ-KG could reverse the suppression of [3H]-TdR incorporation in MCF-7 cells.
Similar results were obtained using flow cytometry where aspartate could reverse the S-phase
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arrest seen in the K-Ras mutant cancer cells, whereas both ɑ-KG and aspartate could only partially
reverse the G1 arrest seen in MCF-7 cells (Fig. 3.2C). Thus, it appears that suppression of aspartate
production by the transaminase reaction catalyzed by GOT is a key factor for inducing S-phase
arrest in response to inhibition of Q utilization. Since aspartate is a metabolite in purine and
pyrimidine biosynthesis, deprivation of aspartate could reduce the pool of nucleotides needed for
DNA synthesis and cause S-phase arrest.
Blocking nucleotide biosynthesis causes an S-phase arrest
The data in Figs 3.1 and 3.2 suggest that the S-phase arrest observed in the absence of Q is due to
lack of Q-derived purine and pyrimidine biosynthesis. We therefore demonstrated whether
suppressing de novo purine and pyrimidine biosynthetic pathways would, like Q deprivation, also
lead to S-phase arrest in K-Ras mutant cancer cells. A rate limiting step in the de novo biosynthetic
pathway for purine nucleotides is conversion of 5-phosphoribosyl-ɑ-pyrophosphate and Q into
glutamate and β-5-phosphoribosylamine, which is catalyzed by phosphoribosyl pyrophosphate
amidotransferase (PPAT). Thus, knockdown of PPAT should block the utilization of Q for purine
nucleotide biosynthesis and mimic Q deprivation. We therefore used siRNA targeted against PPAT
to suppress its expression in the K-Ras mutant cancer cells as well as K-Ras non-mutant cancer
cells. As shown in Fig. 3.3A, complete knockdown of PPAT was observed after 72 hours of
treatment with the siRNA. At this point MDA-MB-231, Calu-1 and MCF-7 cells showed an
increase in S-phase cell populations (Fig. 3.3B). Thus, it shows that manipulation with the de novo
nucleotides biosynthetic pathways disrupts nucleotide pools in the cells and therefore, lead to Sphase arrest in K-Ras as well as K-Ras non-mutant cells.

44

A

MDA-MB-231
Time(hrs) -

Calu-1

MCF-7

48 72 96

-

48 72 96

-

48 72 96

+

-

+

+

-

+

PPAT SiRNA -

+

+

+

+

+

PPAT
Actin

B

MDA-MB-231

MCF-7
S

100

100

G2-M

80

80

80

60

60

60

40

40

40

20

20

20

0

0

0

Scr

PPAT

*

1

PPAT

2

Scr

2

1

100

**

1

*

Scr

S
G2-M

2

120

120

siRNA

G1

G1

120

% cells

Calu-1

PPAT

Figure 3.3- S-phase arrest upon blocking de novo nucleotide biosynthesis pathway. (A) MDAMB-231, Calu-1 and MCF-7 cells were plated at 60% confluence in 6-well plates in CM. After 24 hours,
cells were transfected with either scrambled or PPAT siRNA. Western blot was performed on lysates
collected at the indicated time points to check the levels of PPAT. The data shown are representative of
experiments repeated two times. (B) Cells were prepared as in (A) and then shifted to fresh medium for 96
hours. The cells were collected and flow cytometric analysis was performed for cell cycle distribution by
measuring DNA content/cell. The error bars represent S.D. for experiments repeated two times. p values
for the S-phase population in MDA-MB-231 and Calu-1 cells, across the samples are expressed relative to
control Q. (ns=p>0.05, *=p<0.05, **=p<0.01 ***=p<0.001, ****=p<0.0001)

Glutamine deprivation activates ATR-Chk1 mediated DNA damage pathway
During DNA replication, cells are on high alert for DNA abnormalities such as strand breaks or
base modifications that interfere with replicating the genome. Throughout this process, if anything
is wrong, checkpoints mediated by DNA damage are activated and cell cycle progression stops
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[99, 140]. We postulated that since Q-deprived K-Ras mutant cells lack nucleotides to replicate
the genome, stretches of single stranded DNA would be generated from unreplicated DNA caused
by the lack of deoxy nucleotides. Single stranded DNA breaks stimulates the ATR pathway
whereas double stranded DNA breaks caused by ionizing radiation stimulate the ATM pathway.
In response to unreplicated single stranded DNA, ATR phosphorylates checkpoint kinase 1
(Chk1); and in response to double stranded breaks, ATM phosphorylates Chk2 [141]. We therefore
examined the impact of Q deprivation on the phosphorylation of Chk1 and Chk2 in cells harboring
K-Ras mutations and those without mutations. As shown in Fig. 3.4A, both Q deprivation and
AOA stimulated a robust increase in Chk1, but not Chk2 phosphorylation in K-Ras mutant MDAMB-231 and Calu-1 cells. Neither Q deprivation nor AOA was able to induce Chk1
phosphorylation in the MCF-7 or BJ-hTERT cells that are arrested in G1 phase of the cell cycle
(Fig. 3.4A). These data indicate that in K-Ras mutant cells, glutamine starvation leads to
replication stress due to insufficient precursors for deoxy nucleotides synthesis, which in turn
causes stretches of single stranded DNA that activates the ATR mediated DNA damage pathway
that causes S-phase arrest. In Fig. 3.1, we have shown that the S-phase arrest caused by Q
deprivation can be rescued by addition of deoxy nucleosides. So next thing we wanted to check
whether the stimulation of Chk1 phosphorylation by Q deprivation could be overcome with the
addition of deoxy nucleosides. As shown in Fig. 3.4B, Addition of deoxy nucleosides will repress
the phosphorylation of Chk1 and allows cells to progress in cell cycle. To further establish that the
S-phase arrest observed in K-Ras mutant cancer cells upon Q deprivation was dependent on the
ATR-Chk1 stress response pathway, we investigated whether suppression of Chk1
phosphorylation of Chk1 expression could reverse the S-phase arrest seen with Q deprivation.
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Figure 3.4- Activation of ATR-mediated DNA damage pathway upon deprivation or
inhibition of utilization of the glutamine. (A) MDA-MB-231, Calu-1, MCF-7 and BJ-hTERT cells
were plated at 30% confluence in CM. After 24 hours, cells were transferred to medium with Q, without Q
and medium containing Q and AOA both for 48 hours. Cells were then collected and Western blots were
performed for phospho-Chk1 (Ser345), phospho-Chk2 (Thr68), Chk1, Chk2, and actin. Cisplatin (10µm)
and Hydroxyurea (5mM) treated cells were used as a positive control. The data shown are representative of
experiments repeated two times. (B) MDA-MB-231 and Calu-1 cells were plated at 30% confluence in 10
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cm plates in CM. After 24 hours, cells were shifted to DMEM containing Q or DMEM without Q for 48
hours. At this point, cells were transferred into media lacking Q with or without nucleosides. The lysates
were collected after 24 hours and subjected to western blots analysis for phospho-Chk1 and Chk-1. The
data shown are representative of experiments repeated two times. (C) MDA-MB-231 and Calu-1 cells were
plated at 30% confluence in 10-cm plate in CM. Next day; cells were shifted to media containing no Q
alongside DMSO or MK-8776 (10µM) for 48 hours. Cells were then collected and cell cycle distribution
was determined by flow cytometry. The error bars represent S.D. for experiments repeated two times.
Western blot was also performed to check the phosphorylation of Chk-1 and total Chk-1. The data shown
are representative of experiments repeated two times. p values for the S-phase population in MDA-MB231 and Calu-1 cells, across the samples are expressed relative to control Q. (D) MDA-MB-231 and Calu1 cells were plated at 60% confluence in 6-well plates in CM. After 24 hours, cells were transfected with
either scrambled or Chk-1 siRNA. 48 hours later, cells were transferred to Q-deprived media another 48
hours. Cells were then collected and cell cycle distribution was determined as above. The error bars
represent S.D. for experiments repeated for two times. Western blot was also performed to check the levels
of Chk-1. The data shown are representative of experiments repeated two times. p values for the S-phase
population in MDA-MB-231 and Calu-1 cells, across the samples are expressed relative to control Q.
(ns=p>0.05, *=p<0.05, **=p<0.01 ***=p<0.001, ****=p<0.0001)

We first examined the effect of the ATR kinase inhibitor MK-8776 [142], and as shown in
Fig. 3.4C, this compound suppressed the phosphorylation of Chk1 induced by Q deprivation and
reduced the S-phase population in both MDA-MB-231 and Calu-1 cells. We also examined the
impact of suppressing Chk1 expression with siRNA. As shown in Fig. 3.4D, suppressed Chk1
expression also reduced the population in both the MDA-MB-231 and Calu-1 cells when deprived
of Q. These data further demonstrate that the S-phase arrest in K-Ras mutant cancer cells observed
with Q deprivation is dependent on the ATR-Chk1 stress pathway.
Discussion
We previously reported that K-Ras driven cancers bypass a distinct Q-dependent late G1
checkpoint and arrest in S-phase in response to Q deprivation [10]. Significantly, the cells arrested
in S-phase are selectively killed by rapamycin [139] and other cytotoxic agents [116]. Thus, the
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observation that K-Ras mutant cancer cells arrest in S-phase in response to Q deprivation has
important clinical implications- in that K-Ras itself has been considered as undruggable [143]. In
the study, we have identified the mechanism for S-phase arrest observed with Q deprivation. The
lack of Q led to reduced levels of precursors needed for nucleotide biosynthesis, which induced
replicative stress leading to an ATR and Chk1-mediated S-phase arrest.
The ATR/Chk1 stress response pathway responds to stretches of single stranded DNA
caused by insufficient deoxy nucleotides. Q, a conditionally essential amino acid, serves a critical
anaplerotic agent that feeds the TCA cycle when citrate is shuttled out of the mitochondria for
generating cytosolic acetyl-CoA for fatty acid synthesis in dividing cells. Q can be deaminated
twice to generate the TCA cycle intermediate ɑ-KG, which is just downstream from citrate in the
TCA cycle. However, in K-Ras mutant cancer cells, the conversion of glutamate to ɑ-KG is
accompanied by the conversion of oxaloacetate to aspartate in the transamination reaction
catalyzed by GOT2 [90, 116]. Significantly, the S-phase arrest induced by inhibition of GOT2
could be overcome largely with aspartate. ɑ-KG had little effect on the S-phase arrest induced by
suppression of GOT2. Aspartate exits the mitochondria via the malate-aspartate shuttle that us
usually used for shuttling electrons into the mitochondria, but is also important for generating
cytosolic aspartate that can be contribute to redox balance and amino acid and nucleotide
biosynthesis (Fig. 3.5) [144]. Aspartate is a critical metabolite for purine and pyrimidine
biosynthesis. Several recent reports have similarly identified aspartate derived from several
metabolic pathways as being critical in dividing cells for nucleotide biosynthesis including fatty
acid metabolism [91], the urea cycle [92] and TCA cycle-derived citrate [93, 94]. Consistent with
this role for aspartate, the S-phase arrest of K-Ras driven cancer cells caused by inhibition of GOT
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could also be reversed with deoxy nucleosides and mimicked with suppression of nucleotide
biosynthesis.
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Figure 3.5- Anaplerotic utilization of Q in K-Ras-driven cancer cells. Q is converted to
glutamate (Glu) by glutaminase (GLS). Glu enters the mitochondria via the malate-aspartate (Asp) shuttle
where a transaminase reaction catalyzed by GOT2 converts Glu to a-KG and oxaloacetate (OAA) to Asp.
Asp then exits the mitochondria via the Malate-Asp shuttle where Asp can be converted to OAA by
GOT1. OAA can then be reduced by malate dehydrogenase to malate using NADH. Malate can be
oxidized to pyruvate with concomitant production of NADPH and maintain redox balance. Asp can also
be used for the synthesis of purines and pyrimidines, which are needed for nucleotide biosynthesis.

Collectively, the data provided here reveal that the S-phase arrest observed in K-Ras
mutant cancer cells deprived of Q is due to replicative stress created by the lack of aspartate and
glutamine needed for deoxy nucleotides biosynthesis. Thus, strategies for targeting aspartate
synthesis pathways may be an effective means to sensitize K-Ras driven cancer cells to drugs that
are specific for S-phase-arrested cells.
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Chapter 4: A late G1 lipid checkpoint that is dysregulated in clear cell renal carcinoma
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Abstract
Lipids are important nutrients that proliferating cells require to maintain energy homeostasis as
well as to build plasma membranes for newly synthesized cells. Previously, we have identified
nutrient sensing checkpoints that exist in the latter part of the G1 phase of the cell cycle that are
dependent upon essential amino acids (EAA), glutamine (Q), and finally, a checkpoint mediated
by mTOR, which integrates signals from growth factors and nutrients. In this report, we have
identified and temporally mapped a lipid-mediated G1 checkpoint. This checkpoint is located after
the Q checkpoint and before the mTOR-mediated G1 checkpoint. Intriguingly, clear cell renal cell
carcinoma cells (ccRCC) have a dysregulated lipid-mediated checkpoint. When deprived of lipids,
instead of arresting cells in G1, these cells continue to cycle and utilize lipid droplets as a source
of lipids. Lipid droplets have been known to maintain endoplasmic reticulum (ER) homeostasis
and prevent cytotoxic ER stress in ccRCCs. Dysregulation of the lipid-mediated checkpoint forces
these cells to utilize lipid droplets, which could potentially lead to therapeutic opportunities that
exploit this property of ccRCCs.
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Results
Depriving cells of lipids arrests cells in G1
It was recently reported that Ras-driven cancer cells have an acute need for exogenously supplied
lipids [145, 146]. During the course of this study, we noticed that non-Ras-driven cancers were
arrested in G1 [146]. We extended this study to the immortalized human fibroblast cell line BJhTERT. We subjected these cells to serum deprivation and rapamycin for 48 hours which we
demonstrated previously arrested the BJ-hTERT cells in G1 [10].

A

B

Figure 4.1- Depriving cells of lipids arrests cells in G1. (A) BJ-hTERT cells were plated at 30%
confluence in DMEM containing 10% FBS. After 24 hours, cells were shifted to complete medium (CM),
no growth factors (-GF), medium containing 10% delipidated serum (-Lipids), or CM containing rapamycin
(+Rapa) for 48 hours. After which, the cells were harvested and analyzed for cell cycle distribution by
measuring DNA content/cell. The CM contained 10% dialyzed FBS instead of 10% FBS. Error bars
represent the standard deviation from independent experiments repeated for 3 times. (B) BJ-hTERT cells
were plated and shifted to conditions explained above. Cells were labeled with [3H]-TdR for the final 24
hours of treatment, after which the cells are collected and the incorporated label was determined by
scintillation counting. Values were normalized to the cpm for CM, which was given a value of 100%. Error
bars represent the standard deviation for experiments repeated for 3 times.

As shown in Fig. 4.1A, these treatments caused a G1 cell cycle arrest as determined by
flow cytometry, which measures the DNA content per cell. There was an increase in cells with
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G1 DNA content and reduction in the amount of S-phase and G2/M DNA content indicating a G1
arrest. We also treated the BJ-hTERT cells with delipidated serum and observed a similar increase
in G1 DNA content and reduction in S-phase and G2/M DNA content cells (Fig. 4.1A) – indicating
a G1 arrest. We also measured the effect of lipid deprivation on DNA synthesis as measured by
the uptake of [3H]-TdR. The BJ-hTERT cells were treated as in Fig. 4.1A except that [3H]-TdR
was added for the last 24 hours of treatment. As shown in Fig. 4.1B, [3H]-TdR incorporation was
dramatically reduced with all three treatments. While the reduction in [3H]-TdR with delipidated
serum was not quite as strong, this was likely due to the inability to remove all lipids from serum.
These data demonstrate that in response to lipid deprivation, BJ-hTERT fibroblasts arrest in G1.
Lipid deprivation arrests cells downstream of the Q checkpoint and upstream of the
mTOR checkpoint
In order to temporally distinguish the lipid G1 cell cycle arrest from the arrest caused serum
withdrawal, EAA and Q deprivation, and rapamycin, we performed a series of sequential blocking
experiments. In brief, cells were exposed to various blocking conditions for 48 hours to cause
complete cell cycle arrest. At this point, the first block was removed and a second block was
applied along with [3H]-TdR for 24 hours. If the second block applied is either at the same point
or downstream of the first block, then [3H]-TdR incorporation should not occur. However, if the
second block site is upstream of the first block, then the cells should progress into S-phase and
incorporate the label. The level of [3H]-TdR incorporated by cells released into complete medium
after a first block was considered to be 100%. We first examined cell cycle progression after a
first block of serum withdrawal (Fig. 4.2A). To better distinguish the effect growth factors from
lipids in serum, the serum withdrawal block included a mixture of lipids (No GF + lipid mix) (see
Experimental Procedures). As reported previously [10], EAA and Q deprivation, as well as
rapamycin treatment prevented significant [3H]-TdR incorporation. If we used delipidated serum
(i.e. growth factors without lipids) as a second block there was still very little [3H]-TdR (Fig. 4.2A).
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These data indicate that the lipid checkpoint is downstream from the growth factor-dependent
restriction point.
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Figure 4.2- Lipid deprivation arrests cells downstream of the Q checkpoint and upstream
from the mTOR checkpoint. BJ-hTERT cells were plated and shifted to various first blocking
conditions for 48 hours as in Fig. 1A. The cells were subsequently shifted to complete medium (CM) or
different second block conditions containing [3H]-TdR for 24 hours, after which the cells were collected
and the incorporated label was determined. First blocks were: (A), no serum (no growth factors) plus lipid
mix (see Experimental Procedures); (B), no EAA; (C), no Q; (D), delipidated serum; (E), rapamycin (20
µM). Error bars represent the standard deviation for experiments repeated at least 3 times. (F) Schematic
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summarizing results from the double block mapping experiments for metabolic checkpoints for EAA, Q,
and lipids that are hypothesized to represent a mammalian START (mSTART). Also shown are the relative
positions of the two restriction points (R1 and R2) that respond to growth factors that have been described
[3, 147].

We next examined the effects of EAA (Fig. 4.2B) and Q (Fig. 4.2C) deprivation as a first
block. In both cases, a second block with delipidated serum still prevented [3H]-TdR incorporation
– indicating that the lipid checkpoint was downstream from both the EAA and Q checkpoints. As
reported previously [10], the Q site was downstream from the EAA site as indicated by the ability
of Q deprivation to prevent [3H]-TdR incorporation when EAAs were restored (Fig. 4.2B);
whereas, deprivation of EAA as a second block did not suppress [3H]-TdR incorporation if the
first block was Q deprivation (Fig. 4.2C). If the first block was delipidated serum, the re-addition
of non-delipidated serum and a second block with either EAA, Q, or growth factor deprivation did
not suppress [3H]-TdR incorporation (Fig. 4.2D). In contrast, rapamycin treatment did prevent
[3H]-TdR incorporation observed when non-delipidated serum was provided (Fig. 4.2D). And
lastly, if the first block was rapamycin, a second block with delipidated serum did not prevent
[3H]-TdR incorporation (Fig. 4.2E) - indicating that the lipid checkpoint is upstream from the
mTOR-dependent checkpoint. Collectively the data in Fig. 4.2 demonstrate that the site in G1
where cells arrest in response to lipid deprivation is between the Q checkpoint and the mTOR
checkpoint (Fig. 4.2F).
Effect of Lipid deprivation on cancer cell proliferation and cell cycle progression
We previously reported that cancer cells harboring Ras mutations bypassed the Q checkpoint and
arrested in S-phase instead [10, 116]. We therefore examined the impact of lipid deprivation on
several human cancer cell lines to determine whether there are similar bypasses of the G1 lipid
checkpoint. We examined the impact of lipid deprivation on MDA-MB-231 and MCF-7 breast,

56

A

B

C

D

E

F

G

H

Figure 4.3- Effect of lipid deprivation on cancer cell proliferation and cell cycle progression.
(A-F) MDA-MB-231, Calu-1, DU-145, MCF-7, 786-O and RCC4 cells were plated at 30% confluence in
CM in 10 cm plates. After 24 hours, cells were shifted to complete medium (CM) or medium containing
delipidated serum for 48 hours, at which time the cells were harvested, fixed, stained with propidium iodide,
and analyzed for distribution in G1 and S-phase of the cell cycle by measuring DNA content/cell as
described in Experimental Procedures. The percentage of G1 and S-phase cells in CM relative to that in
delipidated serum is presented. Error bars represent the standard deviation from experiments repeated 3
times. (G) The cells were plated in CM in 12-wells plate and treated with conditions as explained in A.
Cells were labeled with [3H]-TdR for the final 24 hours of treatment, after which the cells are collected and
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the incorporated label was determined by scintillation counting. Values were normalized to the cpm for
CM, which was given a value of 100%. Error bars represent the standard deviation for experiments repeated
for 2 times. (H) MDA-MB-231 and 786-O cells were plated in CM as above. After 24 hours, cells were
shifted to medium containing 10% delipidated serum. At indicated time points, cells were harvested, and
counted using Crystal Violet die. Error bars represent the standard deviation from experiments performed
for 2 times. (ns=p>0.05, *=p<0.05, **=p<0.01, ***=p<0.001, ****=p,0.0001)

Calu-1 lung, DU-145 prostate, 786-O and RCC4 renal cancer cell lines. As shown in Fig. 4.3,
MDA-MB-231 breast (Fig. 4.3A), Calu-1 lung (Fig. 4.3B), DU-145 prostate (Fig. 4.3C), and
MCF-7 (Fig. 4.3D) cancer cells all displayed an increase in G1 DNA content and a reduction in Sphase DNA content in response to lipid deprivation- indicating the G1 cell cycle arrest. However,
both 786-O (Fig. 4.3E) and RCC4 (Fig. 4.3F) renal cancer cell lines do not arrest in G1 as indicated
by a reduced levels of cells with G1 DNA content. While there tended to by somewhat higher
levels of cell with S-phase content with lipid deprivation in the renal cancer cell lines (Fig. 4.3E
and 4.3F), the cells were not arrested in S-phase as indicated by continued DNA synthesis and
uptake of [3H]-TdR in the 786-O and RCC4 cells. In addition, 786-O cells continued proliferation
leading to increased cell number in delipidated serum; whereas MDA-MB-231 cells ceased
proliferation in delipidated serum (Fig. 4.3H). However, after 4 days, the 786-O cells started to
die. Thus, unlike the S-phase arrest observed with Q deprivation in Ras-driven cancer cell line [10,
116], the renal cancer cells did not arrest in S-phase in response to lipid deprivation.
Effect of prolonged lipid deprivation on clear cell renal cancer cells
Both of the renal cancer cell lines used have a defect in the Von-Hippel Lindau (VHL) which leads
the stabilization of hypoxia-inducible factor (HIF)1ɑ and HIF2ɑ (RCC4) or just HIF2ɑ (786-O).
We therefore examined the impact of lipid deprivation on cell cycle progression in 786-O with
restored VHL expression. We found that 786-O cells with restored VHL expression were not
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arrested in G1 (Fig. 4.4A). Consistent with this observation, 786-O cells with restored VHL
expression still incorporated [3H]-TdR under conditions of lipid deprivation (Fig. 4.4B). Thus,
the mechanism of bypass apparently does not depend on loss of VHL and stabilized HIF2ɑ.
However, we did notice a difference between the 786-O and the 786-O cells with restored VHL
expression in response to lipid deprivation. If the cells are allowed to proliferate in delipidated
serum, they ultimately die, however the cells with restored VHL died sooner than the parental 786O cells. Consistent with this observation we saw an increase in sub G1 DNA content in the 786O-VHL cells earlier than in the 786-O cells (Fig. 4.4D) – indicating an earlier loss of cell viability
when VHL expression was restored. A hallmark of clear cell renal carcinoma cells is a high
concentration of lipid droplets that is dependent upon the loss of VHL that gives these cells the
clear cell phenotype [115]. So, next we planned to check the levels of lipid droplets in 786-O
Mock and 786-O VHL expressed cells and we found that cells that stably express VHL protein has
less lipid droplets as compared to its counter parts (Fig. 4.4C). Thus, it is possible that the basis
for the lack of arrest is the utilization of the high lipid content of the HIF2ɑ-dependent
accumulation of lipid droplets in 786-O cells. To examine the effect of proliferation in delipidated
serum on the level lipid droplets, we quantified the level of lipids by staining the 786-O cells with
Oil Red O stain followed by extraction and then testing for absorbance at 492 nm to quantify the
level of lipids in cells maintained for 48 hours in complete medium, medium with delipidated
serum, and delipidated serum and the lipid mix. As shown in Fig. 4.4E, the cells maintained in
delipidated serum for 48 hours had a 65% reduction in lipid content. Since lipid metabolism is
regulated by autophagy [148], we examined the ability of lipid deprivation to induce expression
of the autophagy marker LC3B II. MDA-MB-231 cells, BJ-hTERT, and 786-O cells were
maintained in complete medium, delipidated medium, or delipidated medium plus the lipid mix
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for 48 hours at which time the levels of LC3B II were determined by Western blot analysis. As
shown in Fig. 4.4F, only the 786-O cells showed an increase in LC3B II expression upon lipid
deprivation.
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Figure 4.4- Renal cancer cells utilize lipid droplets to progress through the cell cycle. (A) 786O-VHL cells were plated in DMEM containing 10% FBS (CM). After 24 hours, cells were shifted to
complete medium (CM) or medium containing 10% delipidated serum for 48 hours. The cells were then
harvested, fixed, stained with propidium iodide, and analyzed for distribution in G1 and S-phase of the cell
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cycle by measuring DNA content/cell as described in Fig. 1. Error bars represent the standard deviation
from experiments performed for 2 times (ns=p>0.05, *=p<0.05, **=p<0.01, ***=p<0.001,
****=p<0.0001). (B) 786-O Mock and VHL cells were plated in 12-well plates at 30% confluence in CM.
After 24 hours, cells were shifted to CM or medium containing delipidated serum for 48 hours. Cells were
labeled with [3H]-TdR for the final 24 hours of treatment, after which the cells are collected and the
incorporated label was determined by scintillation counting. Values were normalized to the cpm for CM,
which was given a value of 100%. Error bars represent the standard deviation for experiments repeated for
3 times. (C) 786-O-Mock and 786-O-VHL cells were plated in CM as above. After 24 hours, cells were
shifted to medium containing 10% delipidated serum. After 48 hours, cells were stained with Oil Red O as
described in Experimental Procedures. Error bars represent the standard deviation from experiments
performed three times. (D) 786-O-Mock and 786-O-VHL cells were plated in CM as above. After 24 hours,
cells were shifted to medium containing 10% delipidated serum. At indicated time points, cells were
harvested, fixed, stained with propidium iodide, and analyzed for sub-genomic DNA content/cell as
described in Experimental Procedures at the indicated times. Error bars represent the standard deviation
from experiments performed for 2 times. (E) 786-O cells were plated at 40% confluence in RPMI-1640
medium containing 10% FBS for 24 hours. Cells were then shifted to CM, medium containing delipidated
serum or medium containing delipidated serum with lipid mix added. After 48 hours, cells were stained
with Oil Red O as described in Experimental Procedures. Error bars represent the standard deviation from
experiments performed three times. (F) MDA-MB-231, BJ-hTERT and 786-O cells were plated and treated
as explained earlier. Cells were harvested after 48 hours of treatment. The levels of LC3B II and actin were
determined by Western blot analysis. The data shown are representative of experiments repeated at least 2
times (C= Complete medium, D= Delipidated serum, D+L= Delipidated serum with lipid mix).

Collectively, the data in Fig. 4.4 demonstrate that restoring VHL in 786-O cells does not
reestablish a G1 arrest upon lipid deprivation; however, the data do suggest that the high lipid
content in the 786-O cells contributes to the bypass of the G1 lipid checkpoint and prolong the
survival of cells that continue to proliferate when deprived of lipids.
Discussion
In this report, we have characterized and mapped a distinct G1 cell cycle checkpoint that
is dependent on lipids. This checkpoint is in late G1 and appears to be grouped with two other
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metabolic checkpoints that monitor the presence of EAAs and Q. As shown in Fig. 4.2F the lipid
checkpoint maps between the Q checkpoint and the checkpoint mediated by mTOR. We are
proposing that this collection of distinguishable late G1 metabolic checkpoints represent the
evolutionary equivalent of START of the yeast cell cycle [4, 149].
The metabolic checkpoints are flanked by growth factor-dependent checkpoints – the
restriction point [150, 151], and the mTOR-dependent checkpoint [6, 147, 152]. Both of these
growth factor dependent checkpoints have been referred to as a restriction point [122, 147, 151],
but they are clearly distinguishable [10]. A significant difference between the two growth factordependent checkpoints is the point from which you are coming. If you are coming from mitosis,
you need growth factors to get past the first restriction point, which is about 3.5 hours after mitosis
[153]. However, if you are coming from quiescence or G0, you need growth factors, such as
platelet-derived growth factor, to exit G0; and additional growth factors such as insulin-like growth
factor for progression through late G1 [154]. If you are coming from mitosis, there is no apparent
need for growth factors in late G1. However, rapamycin will arrest cells that are coming from
mitosis [10, 152] – indicating that there is a mechanism for activating mTOR that does not need
growth factors present.
mTOR has been referred to as an integrator of both growth factor and nutrient signals and
a controller of cell growth [6, 15]. mTOR has for a long time been known as a sensor of amino
acids [155] and much has been learned recently about the mechanism for amino acids sensing by
mTOR [156]. It has also been proposed that mTOR can respond to both glucose and fatty acids
via the de novo biosynthesis of phosphatidic acid [157, 158] – a metabolite that is critical for the
stability of the mTOR complexes mTORC1 and mTORC2 [39]. It has also been reported that
mTOR can be activated in a manner that is dependent on lysophosphatidic acid acyltransferase
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[159] – a key enzyme in the de novo biosynthesis of phosphatidic acid. Phosphatidic acid is also
a product of glycolysis and therefore can be an indicator of glucose sufficiency. Q is commonly
converted into fatty acids that can be incorporated phosphatidic acid [160], and thusly,
phosphatidic acid can also be an indicator of sufficient Q. Thus, there are several mechanisms by
which mTOR can respond to the same nutrients that are recognized additional metabolic
checkpoints that are distinguishable from the mTOR checkpoint, which also needs growth factor
input as well. The question that emerges from these observations is: why is there an apparent
redundancy of nutrient sensing mechanisms? The finding reported here that there is a distinct
mechanism for sensing lipids compliments the ability to sense EAAs and Q – all of which are
critical sources of carbon and nitrogen needed for cell growth. Clearly the cell needs to monitor
the presence of nutrients carefully before committing to replicating the genome and doubling its
mass. The redundant mechanisms for nutrient sensing underscore the importance of this cellular
function.
In our previous studies characterizing the Q checkpoint in cancer cells, we made the
discovery that Ras-driven cancer cells bypassed this late G1 checkpoint and instead arrested in Sphase [10] due to a need for Q in nucleotide biosynthesis [161]. Of significance, this created a
synthetic lethality for rapamycin [116], which preferentially induces apoptosis in cells arrested in
S-phase [139, 162]. In this report, we identify renal cancer cells as having a defective lipid
checkpoint. Two renal cancer cell lines were shown to bypass the lipid checkpoint and continue
to divide. These renal cancer cells are deficient in the VHL gene that encodes a ubiquitin ligase
for HIFa [163]. HIFa is a transcription factor that promotes a metabolic transformation that causes
lipid droplet accumulation in renal cancer cells that gives them a “clear cell” phenotype [164].
Restoration of the VHL gene did not restore sensitivity to lipid deprivation.

However, it
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diminished the amount of lipid in the cells and shortened the number of cell divisions before cell
death in response to lipid deprivation. These findings indicate that the override of the G1 lipid
checkpoint involved more than loss of VHL and HIFa stabilization. Thus, while this study does
not reveal a mechanistic basis for the G1 arrest in response to lipid deprivation, an important point
that emerges is that the ability to override the lipid checkpoint by renal cancer cells helps to
validate the existence of this lipid checkpoint. The override of this checkpoint in renal cancer cells
may also provide new opportunities for therapeutic intervention in clear cell renal carcinoma.

64

Chapter 5: Conclusion and Future Directions
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Based on the rationale presented in chapter 1, we were able to show that rapamycin was
able to induce apoptosis when cells are in S-phase of the cell cycle, but not when they were in G1phase (Chapter 2). However, we observed a profound effect of rapamycin when cancer cells were
arrested in S-phase over cells progressing through S-phase. Previously, we had shown that K-Ras
mutant cancer cells override the G1 phase of the cell cycle and instead arrest in S-phase. When we
treat cells with rapamycin in glutamine deprived K-Ras mutant cells, we witnessed an intense
apoptotic effect of rapamycin. We did not observe the same effect in wild type K-Ras cells where
cells were undergoing a G1 arrest, mediated by TGF-b. Previous data shown by Gadir et al.,
demonstrated that if cells are arrested in G1/S boundary using Aphidicolin, cells undergo
apoptosis. Aphidicolin is an inhibitor of DNA replication process via inhibition of DNA pol-a. So
we speculated that rapamycin has a more profound apoptotic effect when cells are under replication
stress. Next we investigated if deprivation of glutamine plays any role in causing replicative stress
in K-Ras mutant cells.
So, in chapter 3, we have shown that S and G2-phase arrest, caused by either deprivation
or perturbing metabolism of glutamine, was rescued by addition of nucleosides. Glutamine as well
as aspartate generated from glutamine metabolism, both play a crucial role in de novo nucleotide
biosynthesis. The S-phase arrest is due to activation of the ATR-Chk1 DNA damage pathway.
This observation may shed a light on why rapamycin works more effectively on cells arrested in
S-phase, rather than capable of progressing through S-phase. The questions that arise from these
observations are: Why is activated mTOR necessary during the replication process? Are DNA
damage pathways regulated by mTOR activation? Does mTOR activate any repair mechanism(s)
to rectify the arrest in S-phase? Also, we have shown that activation of K-Ras pathway leads to
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this phenotype observed in these cells but it would be interesting to show how activation of the KRas pathway leads to override of G1 checkpoint resulting in S-phase arrest.
In chapter 4, like amino acid and glutamine mediated late G1 nutrient sensing checkpoints,
we mapped a lipid mediated checkpoint. Lipids are also an important nutrient that provides
building blocks to synthesize plasma membranes and are also used as signaling molecules. We
mapped the lipid-mediated checkpoint after the glutamine-mediated checkpoint and before the
mTOR-mediated growth checkpoint. Clear cell renal carcinomas have dysregulated lipid-mediated
checkpoint and do not arrest upon lipid deprivation. Due to constitutively activated HIFs, these
cells have lipid droplets for which reason they are named “clear cell”. Restoration of the VHL
tumor suppressor was not enough to restore this lipid-mediated checkpoint. However, restoration
of VHL led to an early onset of cell death, which might be due to loss of clear cell phenotype. It
would be interesting to know whether along with VHL, are there any other signaling pathways
responsible to override the lipid-mediated checkpoint? One possibility is PTEN as 786-O cells
lack functional PTEN.
The work presented here shows widespread metabolic dysregulation such as override of
glutamine-mediated checkpoint in K-Ras mutant cells and the lack of lipid-mediated checkpoint
in clear cell renal carcinomas. Thus, exploiting these vulnerabilities could offer innovative
therapeutic strategies.
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Chapter 6: Materials and Methods
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Cells and cell culture conditions
The human cancer cell lines MDA-MB-231, MCF-7, BJ-hTERT, Calu-1, DU-145, 786-O and
RCC-4 cells were obtained from the American Tissue Type Culture Collection (ATCC). The 786O-VHL cells were generated as described previously [165]. All the cells except 786-O were
maintained in Dulbecco’s modified Eagle medium (DMEM) (Sigma, D6429) supplemented with
10% fetal bovine serum (Sigma, F4135). 786-O cells were maintained in RPMI-1640 (Sigma,
R8758) supplemented with 10% FBS.
Antibodies and reagents
Antibodies against cleaved poly-ADP-ribose polymerase (PARP) (Catalog#9541), Akt, phosphoAkt (S473) (#9271), 4EBP1 (#9452), phospho-4EBP1 (T37/46) (#9459), Cyclin A (#4656),
phospho-Chk1 (Ser345) (#2348), phospho-Chk2 (Thr68) (#2197), Chk1 (#2360), Chk2 (#2662),
LC-3B (2775) and actin (#8457) were obtained from Cell Signaling; Antibody against PPAT
(HPA036092) was obtained from Atlas Antibodies; anti-mouse and anti-rabbit HRP conjugated
secondary antibodies were obtained from Promega. For the Glutamine deprivation, Dulbecco’s
modified Eagle medium without Q (D5546), dialyzed fetal bovine serum (F0392), L-glutamine
(G7513), Aminooxyacetate (AOA) (C13408), Di-methyl ɑ-ketoglutarate (DMKG) (349631) and
aspartate (β-MD) (A8291) were obtained from Sigma-Aldrich. Rapamycin (R-5000) was obtained
from LC Laboratories; Torin1 (4247) and lovastatin (1530) were obtained from Tocris
Biosciences; mevalonate (M4667) was purchased from Sigma. MK-8776 (sc364611) was obtained
from Santa-Cruz Biotechnology. Negative control scrambled siRNA (D-001206-13-05), siRNAs
targeted against Chk1 (M-003255-04-0005) and siRNAs targeted against Phosphoribosyl
Pyrophosphate Amidotransferase (PPAT) (M-006003-01-0005) was obtained from Dharmacon.
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Deoxy nucleosides (dNSs) (ES-008-D) was purchased from EMD Millipore. Ultima Gold
scintillation fluid (6013681) and [3H]-thymidine deoxyribose (TdR) (20Ci/mMol, 1mCi/ml)
(NET-027E) were obtained from PerkinElmer. For the EAAs deprivation; DMEM lacking Arg,
Leu and Lys (D9443) and dialyzed FBS (DFBS) (F0392) were ordered from Sigma. For the Q
deprivation, DMEM lacking Q (D5546) and DFBS were used from Sigma. For the lipid
deprivation; delipidated fetal bovine serum (900-123) was obtained from Gemini-Bioproducts,
Fatty acid mixture (11905) was obtained from Invitrogen and fatty acid free bovine serum albumin
(BP9704) was obtained from Fisher Scientific.
Cell cycle synchronization and flow cytometric analysis
Activated 10 mM lovastatin stock solution was prepared by dissolving 10 mg lovastatin in 200 µl
of 95% ethanol, 156 µl of 1N NaOH was then added, pH adjusted to 7.2 using 1M HCl, and finally
diluted to 2.5 ml with sterile-filtered water. After lovastatin treatment, cells were released from
Lovastatin block and plated in complete medium and mevalonic acid, cell cycle distribution was
determined as described previously [10]. Briefly, cells were fixed in 70% ethanol, stained using
propidium iodide, and passed through 70-µm meshes to remove cell aggregates. Fluorescence
intensity corresponding to DNA content in different phase of cell cycle was measured by flow
cytometry (FACSCalibur; Becton Dickinson), and analyzed using WinCycle software (Phoenix
Flow Systems).
Western blot analysis
Proteins were extracted from cultured cells in M-PER (Thermo Scientific 78501). Equal amounts
of proteins were subjected to SDS-PAGE on polyacrylamide separating gels. Electrophoresed
proteins were then transferred to nitrocellulose membrane. After transfer, membranes were
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blocked in an isotonic solution containing 5% non-fat dry milk in PBS. Membranes were then
incubated with primary antibodies as described in the text. Depending on the origin of the primary
antibody, either anti-mouse or anti-rabbit HRP conjugated IgG was used for detection using ECL
system (Thermo Scientific 34080). The dilutions of the antibodies were used as per the
recommended concentrations by the seller.
Cell viability
Cell viability was determined by trypan blue exclusion. Cells were harvested, washed and treated
with trypan blue (Sigma-T8154) at a concentration of 0.4%v/v. After 5 min, trypan blue uptake
(dead cells) was scored using a hemocytometer.
Transient transfections
Cells were plated in 6-well plates in medium containing 10% FBS. The next day, transfections
with siRNAs (100nM) in Lipofectamine RNAi max were performed. After 6 hours, reagents were
replaced with fresh 10% FBS and cells were allowed to incubate for indicated times as explained
in the experiments.
Flow cytometric analysis
Cell cycle distribution was determined by flow cytometry as explained in [10]. Each experiment
was performed in duplicate and two-way ANOVA tests were performed in all statistical analyses.
p values for the S-phase population in cells, across the samples are expressed relative to control
Q.
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Thymidine incorporation assay
Cells were labeled with 1 µCi/ml [3H]-thymidine deoxyribose (TdR). At indicated times, cells
were washed twice with 1ml phosphate-buffered saline and then precipitated twice with 1ml 10%
trichloroacetic acid. The precipitates were solubilized in 0.5ml of 0.5% SDS/0.5MNaOH solution,
and the extent of TdR incorporation was quantified using 75 µl of sample and 3 ml of scintillation
fluid. Each experiment was performed in duplicate and one-way ANOVA tests were performed in
all statistical analyses.
Lipid (Oil Red O) staining
Lipid (Oil Red O) staining kit (MAK194) was purchased from Sigma. The staining was conducted
as per the vendor’s protocol. To measure quantitatively, stained cells were washed 3 times with
60% isopropranolol for 5 min each time with gentle rocking. Oil Red O stain was extracted with
100% isopropranolol for 5 min with gentle rocking. Absorbance at 492nm was measured for the
collected samples and 100% isopropranolol was used as background to subtract the background
signal.
Lipid mix supplementation
Fatty acid mix was obtained from Invitrogen (11905) and was supplied to cells as 1:200 dilution
complexed with 10% bovine serum albumin (BSA) (Sigma) in 2 to 1 ratio for the final
concentration of lipids in the media of 0.375 mg/L.
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